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ABSTRACT 
 
Cyclic adenosine monophosphate (cAMP) and the second messengers that modulate 
several biological processes are regulated by adenylyl cyclase (AC) and cyclic nucleotide 
phosphodiesterases (PDEs). ACs and PDEs are comprised of superfamilies of enzymes that 
are viewed as druggable targets due to their many distinct biological roles and tissue-specific 
distribution. As such, small molecule regulators of ACs and PDEs are important as chemical probes 
to study the roles of individual ACs or PDEs and as potential therapeutics. In the past, our lab has 
expressed 15 mammalian PDE genes in S. pombe, replacing the endogenous Cgs2 PDE. High 
throughput screens for PDE inhibitors identified novel compounds that show relevant biological 
activity in mammalian cell culture assays. The aim of this thesis is to develop tools to understand 
the mechanism of interaction between key regulators of the cAMP pathway and small molecules. 
The current study is comprised of two parts. In the first part of this thesis, I developed a genetic 
screen that detected alleles whose proteins remain active in the presence of BC54 and was to 
confirm the effect of the PDE4BT407A mutation using cell-based assays and in vitro enzyme 
assays. In the second part of this thesis, I developed and carried out HTSs using a PKA-repressed 
GFP reporter that can identify compounds that reduce PKA activity, which would include PDE 
activators and AC or GNAS1 inhibitors. To date, I have identified three AC inhibitors that appear 
to act on several of the ten different mammalian ACs. To our knowledge, this is the first time a 
large HTS has identified AC inhibitors, where inhibition was assessed inside the cells. The findings 
in this thesis will be useful in the design of more effective PDE inhibitors and in the development 
of novel chemical probes for studying cAMP signaling in mammalian cells. 
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CHAPTER ONE 
 
INTRODUCTION 
 
1.1 Cyclic nucleotide signaling  
Cyclic nucleotides, cyclic adenosine monophosphate (cAMP) and cyclic guanosine 
monophosphate (cGMP), are second messengers that modulate several physiological processes, 
such as cognitive functions, inflammation, and endocrine signaling among others (Beavo and Conti, 
2007; Bender and Beavo, 2006). The identification of cAMP led to the development of many 
studies to uncover the components of the cAMP pathway in many biological processes (Sutherland, 
1958). Therefore, understanding their role in different biological responses may be useful for 
medicinal therapeutics. 
In eukaryotes, the cAMP pathway initiates with the recognition of a signaling molecule such as a 
neurotransmitter by seven-transmembrane domain G protein coupled receptors (GPCRs) that 
activate heterotrimeric guanine nucleotide-binding proteins (G proteins). The activated G protein 
then goes on to stimulate adenylyl cyclases (ACs) that convert ATP to cAMP (Offermanns, 2001; 
Sunahara et al., 1996) (Figure 1.1a). In addition, the rate of conversion of cAMP to 5’AMP is 
regulated by cyclic nucleotide phosphodiesterases (PDEs) (Beavo and Conti, 2007). Therefore, the 
intracellular cAMP levels are controlled by the rate of synthesis by ACs and hydrolysis by PDEs, 
which elicit a cell response to environmental changes (Figure 1.1b) (Beavo and Conti, 2007). 
 
1.2 Cyclic nucleotide signaling in mammals 
In mammalian cells, this cAMP signaling cascade is a very complex pathway with superfamilies 
of proteins that have the same biochemical activity as described in the following sections (Stratakis, 
2012; Gancedo, 2013; Maurice et al, 2014, 2006). Once synthesized, cAMP targets numerous 
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cellular effector proteins, such as: cyclic nucleotide-gated ion channels (CNGs), protein kinase A 
(PKA) and GTPases that are “exchange proteins directly activated by cAMP”, known as Epacs 
(Steegborn, 2014) (Figure 1.1a).  
 
1.3 Mammalian Cyclic nucleotide Phosphodiesterases (PDEs) 
One of the ways to regulate the intracellular levels of cAMP and cGMP is by their rate of 
degradation (Figure 1.1b). The temporal and spatial distribution of cyclic nucleotides 
monophosphate (cNMPs) is controlled, in part, by hydrolysis by PDEs (Bender and Beavo, 2006). 
In mammals, PDEs are grouped into 11 families encoded by 21 genes that produce more than 100 
isoforms. This classification is based on sequence conservation, kinetics and inhibitor sensitivity 
(Keravis and Lugnier, 2012; Beavo and Conti, 2007) (Table 1.1). Furthermore, PDEs are 
subdivided according to substrate preference of hydrolyzing either cAMP (PDEs 4, 7 and 8) or 
cGMP (PDEs 5,6 and 9) or both (PDEs 1,2,3,10 or 11) (Beavo and Conti, 2007) (Figure 1.2a).  
Mammalian PDE families also share a conserved catalytic domain of approximately 270 amino 
acids, located near the C-terminus, and regulatory domains, in most cases located at the protein N 
terminus (Beavo and Conti, 2007; Bender and Beavo, 2006; Lugnier, 2006), that vary for each PDE 
from calmodulin binding sites to GAF domains, PAS domains and auto-inhibitory sequences 
(Lugnier, 2006). Also, PDEs share about 50% sequence homology in the catalytic domains with 
PDEs from other families (Keravis and Lugnier, 2012). The catalytic domain has been well 
characterized, especially with respect to three sites. The M site is a metal ion-binding site, which is 
coordinated by two histidine residues and two aspartic acid residues that form the residue 
recognition sequence for cNMPs. The Q site is the core pocket that contains the hydrophobic clamp. 
The S pocket is filled with a water molecule network, and is composed of hydrophilic amino acids 
including the Q site (Houslay et al., 2005). Moreover, early structural studies suggested that a 
glutamine residue located in the binding pocket functions in stabilizing the binding of the purine 
ring to the binding pocket and, consequently, dictating substrate-specificity for each PDE family 
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(Zhang et al., 2004b; Xu et al., 2000). However, recent studies suggest the differences in preference 
for either cAMP or cGMP may be due to additional residues in the active site across PDEs, which 
can also modulate the shape and size of the active sites in the various isoforms (Ke et al., 2011). 
In addition, individual PDE isoforms display a unique tissue-specific distribution and subcellular 
localization due to alternative splicing and/or expression from multiple promoters (Lerner and 
Epstein, 2006; Maurice et al., 2003; Mehats et al, 2002). The distinct intracellular localization of 
PDEs allows individual PDEs to play greater or lesser roles in the regulation of a myriad of specific 
physiological processes (Figure 1.2b). Therefore, PDEs are viewed as useful targets for 
pharmacological inhibition to treat variety of diseases due to their many distinct biological roles, 
tissue-specific expression and subcellular localization (Lerner and Epstein, 2006; Maurice et al., 
2003). However, this subcellular localization is not completely understood and, researchers have 
suggested three different functional purposes for it, as follows: as a barrier where the PDE is 
functionally blocking cAMP diffusion; as a sink, by generating low cAMP microdomains; as 
compartment-sequestered regulator by allowing for equilibrium between compartments by 
appearing in different concentrations (Richter et al, 2013). The unique temporal and spatial 
expression of PDEs contributes to their diversity, but it also makes it difficult to understand their 
biological roles. In order to understand the individual function and utilize them as potential 
therapeutics, it is essential to identify selective PDE modulators (inhibitors and activators) that 
target individual PDE families as well as individual subtypes within a family.  
 
1.4 Phosphodiesterase 4 (PDE4) family 
In mammals, the PDE4 family is the largest of the PDE families and consists of four genes (PDE4A, 
PDE4B, PDE4C and PDE4D) that undergo alternative splicing and yield many splice variants 
(Beavo and Conti, 2007; Omori and Kotera, 2007). There are greater than 20 PDE4 isoforms, as 
follows: 7 PDE4A variants, 4 PDE4B variants, 7 PDE4C variants and 11 PDE4D variants (Figure 
1.3a). The PDE4 subtypes have higher affinity for cAMP when compared to cGMP. A compilation 
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of in vitro studies characterized their Km ranging from 1 to 5uM. (Beavo and Conti, 2007) (Table 
1.1). 
 
1.4.1 PDE4 structure and regulation 
The PDE4 variants have 75% identical catalytic domains with conserved C-termini and variable 
N-termini such that they can be grouped as length variants (Beavo and Conti, 2007). The PDE4 
isozymes differ structurally based on the presence or absence of the regulatory domains termed 
Upstream Conserved Regions 1 and 2 (UCR1 and UCR2) located in the N-terminus (Maurice et 
al., 2014). The presence or absence of UCRs determines a variant length and they are classified as 
long form (possesses both UCR1 and UCR2 regions), short (possesses the UCR2 region only), 
super-short (contains only half of UCR2 region) (Figure 1.3b) (Richter et al., 2013). 
PDE4 enzymes possess various regulatory domains as follows: ERK phosphorylation domain in 
the C-terminus; the UCRs separated by linker regions 1 and 2 (LR1 and LR2) at the N-terminus; a 
PKA regulatory domain in the UCR1 directly correlated to the catalytic activity of PDE4 long 
forms when phosphorylated at a Serine54 (Lerner and Epstein, 2006), and a dimerization site 
(Figure 1.3b) (Lugnier, 2006). In addition to the PKA domain, the UCR1 site contains a 
phosphatidic acid binding site that acts as an allosteric activator of the PDE4D3 protein (Grange et 
al., 2000).  
The presence of PKA phosphorylation site in the N-terminus inhibits ERK regulatory activity in 
the C-terminus in long form variants. Conversely, the absence of PKA domain in the N-terminus 
allows ERK to activate PDE activity in short forms (Lerner and Epstein, 2006). The UCR-
containing region of long form PDE4s is also involved in dimerization. The presence of 
dimerization promotes sensitivity to rolipram (the drug that defines the PDE4 family) (Richter and 
Conti, 2004) along with conformational modifications (Conti et al., 2003). These changes in the 
PDE4 affect the affinity for rolipram and are classified as either low-affinity rolipram binding site 
(LARBS) and high-affinity rolipram binding site (HARBS) (Houslay et al., 2005). Moreover, 
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Figure 1.1. Overview on cAMP signaling pathway A) A signaling molecule is recognized by 
GPCR. This binding causes a conformational change that sends a signal to activate Gα, which in 
turn, stimulates AC. AC converts ATP to cAMP, which can then be hydrolyzed by PDE. Once 
cAMP is produced, it activates the cAMP effectors in mammalian cells: exchange proteins 
activated by cAMP (EPACS), cyclic nucleotide gated ion channels (CNGs) and PKA that triggers 
cellular responses. B). cAMP levels are regulated by the rate of synthesis from ATP by adenylyl 
cyclase and hydrolysis by PDEs producing 5’AMP. 
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Figure 1.1 Overview on cAMP signaling pathway 
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Figure 1.2. Characteristics of mammalian PDEs. A) Mammalian PDE families subdivided 
according to substrate specificity. cAMP specific PDEs are in the pink circle, cGMP specific PDEs 
are in the blue circle and dual PDEs are in both circles. B) cAMP specific PDEs are involved in 
several biological processes (from left to right: cognition and memory, endocrine function, heart 
and respiratory tract function, inflammation, cell proliferation and differentiation), implicating in 
many potential therapeutics (Images found using Google search engine). 
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dimerization is important for stabilization of PDE4 long forms and the regulation of its activity via 
post-translational modifications, but not required for high-affinity rolipram binding (Richter and 
Conti, 2004).  
According to the PDE4B2 crystal structure, the catalytic domain structure is composed of residues 
152 to 487. The catalytic site is comprised of three functional groups of residues that are responsible 
for the following: hydrolysis, nucleotide recognition and hydrophobic clamp (Figure 1.4a) 
(Houslay et al., 2005). Crystal structure studies of PDE4 enzymes have facilitated our 
understanding of residues involved in substrate binding, conformational changes that are essential 
for PDE4 catalytic activity, and the residues involved in binding of PDE4 inhibitors (Figure 1.4b) 
(Xu et al., 2000, Conti et al., 2003, Houslay et al., 2005). These studies also have allowed drug 
design targeting PDEs as a therapeutic approach for many biological disorders. Many PDE small 
molecule inhibitors have been the subjects of clinical trials (Table 1.2). 
 
1.4.2 Tissue distribution and Biological roles of PD4B2 and PDE4B3 
The PDE4 mRNAs have a ubiquitous tissue distribution (Lerner and Epstein, 2006; Beavo and 
Conti, 2007). They can be found in cardiovascular tissue, smooth muscles and inflammatory cells, 
muscle and brain (Keravis and Lugnier, 2012). More specifically, PDE4B subtypes are localized 
in human immune and inflammatory cells, consistent with their immune response and inflammatory 
roles (Keravis and Lugnier, 2012) and they are predominantly found in human monocytes and 
neutrophils (Wang et al., 1999). Moreover, both PDE4B and PDE4D are expressed in 
cardiomyocytes of rodents and humans (Maurice et al., 2003) with PDE4D3 being highly expressed 
in the heart muscle (Houslay et al., 2007). In addition, PDE4D mRNA is highly expressed in the 
mural granulosa cells, cells from female reproductive system (Tsafriri et al., 1996). 
PDE4 proteins are found at relatively high concentrations in the brain (Richter et al., 2013) where 
they play a role in cognition (Richter et al., 2013) as the main PDE involved in learning and memory 
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(Keravis and Lugnier, 2012). As such, PDE4B and D mutations are associated with anxiety 
behavior and in neurogenesis along with depression and memory, respectively (Titus, et al., 2014).  
Therefore, PDE4 proteins are seen as a good pharmacological target for the treatment of conditions 
affecting a myriad of biological processes, such as: immune and inflammation, myocardium and 
smooth muscle contractility, angiogenesis, and cognition, among others (Figure 1.2b) (Ricciarelli 
and Fedele, 2015; Richter et al., 2013, Maurice et al., 2014; Houslay et al., 2005). However, the 
broad tissue distribution of the PDE4 family suggests the likelihood of side effects, as the emetic 
response associated with PDE4D inhibition (Robichaud, 2002). 
 
1.4.3 PDE4 inhibitors 
PDE4 has been targeted for drug development for the treatment of many biological disorders 
mentioned in the previous section (Houslay et al., 2005). The difficulty in developing PDE 
inhibitors lies in generating effectiveness against isoforms that share a conserved catalytic domain 
sequence and in understanding of the LARBS and HARBS conformational states (Wang et al., 
2007). These characteristics create a challenge to generate selective PDE4 inhibitors for specific  
isoforms that can decrease or abolish side effects (Wang et al., 2007, Xu et al., 2000). However, 
most PDE4 compounds do not show subtype selectivity (Wang et al., 2007).  
As already mentioned, in recent years, crystal structure studies have allowed scientists to better 
understand amino acid interactions involved in the PDE activity, which, in turn, have stimulated 
the development of drug design studies for therapeutic approaches. These studies aim to identify 
compounds that either interact with the catalytic domain directly or, indirectly, via allosteric sites 
(Wang et al., 2007; Card et al., 2004). Most inhibitors, but not all, bind to enzymes at the active 
site, competing directly with the substrate (Copeland, 2000). However, other inhibitors are 
allosteric effectors, binding to a distinct site other than the active site, inhibiting the enzyme in a 
non-competitive manner by promoting a conformational change in the enzyme (Copeland, 2000).  
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Table 1.1 Properties of PDE enzymes* 
 
*Modified from Keravis and Lugnier (2012) and Bender and Beavo (2006) 
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Figure 1.3. PDE4 Isoforms and regulatory domains. The PDE4 family is composed of four genes 
(PDE4A-D). A) Each gene has multiple variants: at least, 7 PDE4A variants, 4 PDE4B variants, 7 
PDE4C variants and 11 PDE4D variants. Asterisks indicate the PDE4 isoforms addressed in this 
study (PDE4B2, super short form; PDE4D2, short form; and PDE4D3, long form). B) The domains 
represented as barrels connected by wires indicating linker regions. Long red barrels correspond to 
the catalytic domains and short red barrels correspond to the conserved C-termini; Blue circles 
represent phosphorylation sites for protein kinase A (PKA) and extracellular signal-regulated 
kinase 2 (ERK2), The lengths of PDE4 variants are distinguished by the complete or partial 
presence of the UCR1/UCR2 regions (in pink and purple barrels) respectively, and UCR domain 
regions mediating dimerization are represented by a black rectangle (Modified from Houslay et al., 
2005). 
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Figure 1.4. PDE4B2 crystal structure and residue interactions. A) Three groups involved in aspects 
of PDE function: hydrolysis, nucleotide recognition and hydrophobic clamp (image belongs to 
Houslay et al., 2005) B) PDE4B2 catalytic domain (residues from 152 to 487) is formed by 17 α-
helices that are divided in three groups, as follows: the yellow group (residues 152 to 274) located 
in the C-terminus, the middle group in green (residues 275 to 347 and blue group (residues 348 to 
487) located in the N-terminus domain (Modified from Xu et al., 2000). 
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Figure 1.4 PDE4B2 crystal structure and residue interactions  
A                                             B 
 
 
 
 
 
 
 
  
17 
 
Table 1.2. PDE4 inhibitors currently in clinical trials 
 
Modified from Maurice et al., 2014 (not all PDE4 inhibitors are listed) 
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There are different ways to develop new PDE inhibitors. The first approach is to generate allosteric 
modulators. To date, researchers have successfully used this approach to target many GPCRs for 
treatment of CNS disorders (Conn et al., 2009) or to inhibit PDE4D, the PDE4 subtype involved in 
several CNS conditions, with the ability to reduced emetic response by determining the emetic 
threshold in three species via oral administration (Burgin et al., 2010). In addition, inhibitors have 
been computationally designed based on co-crystal structure of PDE4 enzymes bound to inhibitors 
(Houslay et al, 2005). The second approach is through chemical screens using either in silico (Card 
et al., 2004) or cell-based assays (Ceyhan et al., 2012; Demirbas, et al., 2010). Recently, several 
studies have tested compounds targeting more than one PDE family, such as PDE4 and PDE7 that 
are both cAMP-specific PDE involved in inflammatory response (Maurice et al., 2014). A third 
approach has been used to identify compounds that produce synergistic effects by either inhaling 
the inhibitors or developing antisense oligonucleotides targeting specific PDEs (Maurice et al., 
2014). For instance, treatment of combined PDE7A and PDE4 family using specific antisense 
oligonucleotides (AON) effectively reduced the inflammatory response to sub-acute smoke-
induced model exposure in mice correlating reduction of neutrophils recruitment with reduction of 
mRNA levels of PDEs tested, and reduction of chemokine levels in human broncho-epithelial cells 
in vitro (Fortin et al., 2009). Our lab has identified a dual-specificity PDE4/7 inhibitor (BC54) that 
seems less active against PDE4D (the PDE4D responsible for emesis) than it is against PDE4A and 
PDE4B in our yeast assay, although it displays similar potency to all three subtypes in vitro 
(Hoffman laboratory, unpublished data). Thus, BC54 may be able to elicit a greater anti-
inflammatory response with reduced side effects. Chapter 2 of my thesis describes a genetic 
approach to examine the interaction of BC54 with PDE4B, while Appendix B examines the 
effectiveness of BC54 derivatives as a way of investigating functional groups of the compound. 
 
1.5 Clinical trials of PDE4 inhibitors 
19 
 
Over the years, a large number of trials for PDE4 enzymes have been conducted (US National 
Institutes of Health, 2015). These involve compounds that fall into four main chemical classes: 
catechol, xanthane, pyrozole and purine analogs (Figure 1.5a) (Houslay et al., 2005). The first 
generation of PDE inhibitor studies were carried out with non-selective PDE inhibitors such as 
theophylline, a weak PDE4 inhibitor that is a xanthine derivative (Houslay et al., 2005). It has been 
tested for asthma and chronic obstructive pulmonary disease (COPD) treatment along with 
bronchodilators. However, it produces too many side effects to be used in these conditions (Spina, 
2008). 
Rolipram, a first generation PDE4 inhibitor, is selective PDE inhibitor (Castro et al., 2005). 
Rolipram has been used as a model to generate selective PDE4 inhibitors (Houslay et al., 2005). 
Over the years, many clinical trials were conducted testing second generation PDE4 inhibitors 
(Figure 1.5b). The second generation of PDE4 inhibitors were developed following the discovery 
of rolipram and its distinct binding affinity to the long (IC50 varying from 1 to 50 nM) or short 
forms (IC50 varying from 0.1 to 1 µM) of PDE4 (Houslay and Adams, 2003).  
Early studies in rats and humans identified rolipram as a PDE4 inhibitor that promoted 
antidepressant and behavioral effects (Wachtel, 1982; Wachtel, 1983; Zeller et al., 1984). In 2005, 
clinical trials for asthma tested many compounds, such as: rolipram, zardaverine, filamilast, 
piclamilast, tetomilast among others. But many of these compounds have been discontinued due to 
side effects or lack of effectiveness (Houslay et al., 2005). After that, compounds that appear to be 
less emetic were developed for asthma and entered either Phase I (tofimilast, an indazole or 
ibudilast; and pyrazolopyridine, used for asthma, but also tested for multiple sclerosis trials) or 
Phase II trials (YM-976, pyridopymidinone, and lirimilast, but both were discontinued possibly due 
to emetic effects) (Houslay et al., 2005).  
Although rolipram causes emesis, it has shown some promise, but it is not a good drug to treat 
conditions like depression and Huntington’s disease (Maurice et al., 2014). It inhibits the 
production of TNF-alpha, a pro-inflammatory cytokine produced by monocytes, macrophages and 
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T cells (Jimenez et al., 2001). In recent years, Roflumilast, a catechol inhibitor that resembles 
rolipram, has been approved for the treatment of COPD (FDA, 2011). In a recent clinical trial, 
roflumilast was tested in 36 obese women w/ polycystic ovary syndrome (PCOS) and the combined 
treatment of roflumilast and metformin, an antidiabetic medication, promoted body weight 
reduction via fat mass loss (Jensterle et al., 2014).  
The latest generation of PDE4 inhibitors, apremilast, seemed promising for trials for autoimmune 
conditions, presenting fast absorption (Kumar et al., 2013). Inhibition of PDE4 by apremilast has 
promoted TNFα inhibition in human cells (Harrison, 2013) and was approved by the FDA for 
psoriatic arthritis last year (FDA, 2014). 
Currently, there are many ongoing trials testing compounds that target PDE4 enzymes for different 
pathologies (Table 1.2) (Maurice et al., 2014). For PDE4 isoenzymes targeted for therapeutics, the 
conditions range from autoimmune disorders like psoriasis, apondylitis and arthritis (Kumar et al., 
2013; Loukides et al., 2013; Castro et al., 2005; Ariga et al, 2004), fertility (Jin et al, 1999); asthma 
and COPD (Fabbri et al., 2009; Schalkwyk, et al, 2005), airway smooth muscle contraction (Mehats 
et al, 2003), CNS conditions (Houslay et al., 2005), and cancer (Lin et al., 2013).  
Although many PDE4 inhibitors have been designed and placed in clinical trials, there have been 
a wide range of side effects associated to their use. The common side effects are nausea, headache 
and emesis (Kumar et al., 2013; Spina, 2008; Calverley et al., 2007; Houslay et al., 2005; Lipworth, 
2005). Therefore, there is still a need to discover new PDE4 inhibitors that can be both selective 
and potent, yet produce relatively few side effects.  
 
1.6 Phosphodiesterase 7 (PDE7) family 
The PDE7 family consists of two genes (PDE7A and PDE7B). Each PDE7 gene has three splice 
variants Conti and Beavo, 2007). In addition, PDE7B gene codes for an additional variant (Keravis 
and Lugnier, 2012). To date, there are no known regulatory sites in the N-termini of PDE7 proteins 
(Keravis and Lugnier, 2012). The PDE7 proteins have wide tissue distribution and subcellular 
21 
 
location, being expressed in lymphocytes and proinflammatory cells (PDE7A1), skeletal and 
cardiac muscle (PDE7A2), striatal neurons (PDE7B1) (Keravis and Lugnier, 2012). This tissue 
specific expression and localization has suggested that PDE7A1 has immune and inflammatory 
roles (Giembycz and Smith, 2006; Lee et al., 2002) and PDE7B1 may be involved in cognition and 
memory (Sasaki et al., 2004).  
Expression of PDE7A is required during regulation of CD3- and CD8- for T cell activation and IL-
2 production (Soderling and Beavo, 2000; Linsong et al., 1999). PDE7B splice variants (PDE7B1, 
PDE7B2 and PDE7B3) are also expressed in several tissues including brain, heart, skeletal muscle 
and pancreas (Sasaki et al., 2002; Hetman et al., 2000; Sasaki et al., 2000) and PDE7B1 transcript 
was the only one activated by agonist response in striatal neurons via the cAMP pathway, 
suggesting a role in memory function (Sasaki et al., 2004). Overall, there is a 70% homology  
between PDE7A and PDE7B within the 270 amino acids in the catalytic domain (Gardner et al., 
2000).  
 
1.6.1 Tissue distribution and biological roles of PDE7  
The PDE7 family is expressed in several tissues including brain, heart and muscle. Inhibiting both 
PDE7A and PDE4 family using specific antisense oligonucleotides (AON) effectively reduced the 
inflammatory response in a sub-acute smoke-induced exposure model in mice (Fortin et al., 2009). 
Inhibition of PDE7A enzyme reduced spinal cord tissue injury and inflammation (Paterniti et al., 
2011). Furthermore, PDE7B expression is increased in B cells during chronic lymphocytic 
leukemia (CLL) and use of PDE7 inhibitor along with dual PDE4/7 inhibitor appears to decrease 
leukemic cells at concentrations that have low toxicity effects in normal B cells (Zhang et al., 2008). 
In disease studies, understanding the functions of PDE7 enzymes has the potential to develop good 
therapeutic targets. 
However, there is a lack of selective inhibitors for PDE7 enzymes (Maurice et al., 2003). There are 
a couple of PDE7 inhibitors currently undergoing clinical trials (Maurice et al., 2014) (Table 1.2)  
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Figure 1.5. Structure of PDE4 inhibitors. A) There are four main compound classes used in the 
design of PDE4 inhibitors, as follows: catechol, xanthane, pyrozole, purine analogs (Images 
modified from Wikipedia) B) Many PDE4 inhibitors have been used for clinical trials: Rolipram, 
Zarvaderine, cilomilast roflumilast, Piclamilast, are second generation of PDE4 inhibitors and 
Theophyline, a non-selective first generation PDE4 inhibitor (Modified from Houslay et al., 2005). 
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Figure 1.5 Structure of PDE4 inhibitors  
A 
 
B 
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and, thus far, there is only one commercially-available compound BRL50481 (Smith et al, 2004), 
which it is not very active against PDE7B (Alaamery et al., 2010). A previous study from our lab 
identified compounds that inhibit PDE7B, but the mechanism of inhibition is not completely 
understood due to a lack of PDE7B crystal structure characterization (Alaamery et al., 2010). 
Moreover, additional data suggest that some of these compounds may bind allosterically to PDE 
enzymes, instead of blocking the cAMP binding site (Alaamery et al., 2010). Therefore, it is 
reasonable to think that PDE7s can be regulated at another site other than the cAMP binding site.  
As mentioned above, one idea in drug development is to target both PDE4 and PDE7 proteins 
(Maurice et al., 2014). These proteins are expressed in inflammatory cells (Maurice et al., 2014; 
Keravis and Lugnier, 2012) and treatment of both PDE4 and PDE7 have reduced inflammation in 
many studies (Giembycz and Newton, 2011; Tenor et al., 2011; Fortin et al., 2009; Smith et al., 
2004), suggesting a possible synergistic effect in the reduction of inflammation (Maurice et al., 
2014). Therefore, a dual PDE4/7 inhibition approach could be a good therapeutic treatment for 
inflammatory conditions like COPD and asthma. The dual PDE4/7 inhibitor BC54 that is the focus 
of Chapter 2 of this thesis could possibly generate a greater anti-inflammatory response before 
reaching levels that cause emesis, however more needs to be known about its mechanism of action 
to help guide its development from a promising lead compound to an actual drug (Section 1.8.1). 
 
1.7 Mammalian adenylyl cyclases 
Adenylyl cyclases (ACs) and guanylyl cyclases (GCs) are enzymes responsible for the conversion 
of adenosine triphosphate (ATP) or guanosine triphosphate (GTP) to cAMP and cGMP, 
respectively, with release of pyrophosphate (Hartwig et al., 2014; Kamenetsky et al., 2006). ACs 
along with GCs comprise six distinct classes of proteins that are evolutionarily defined by sequence 
homology within their catalytic domain (Kamenetsky et al., 2006). In mammalian cells, there are 
10 isoforms of AC enzymes and they belong to nucleotidyl cyclase family class III (Nicol and 
Gaspar, 2014; Kamenetsky et al., 2006). AC isoforms are encoded by ten different genes (Table 
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1.3) (Hanoune et al., 1997). These isoforms are divided in two types: AC1 to AC9 are 
transmembrane adenylyl cyclases (tmACs), while the tenth AC is a soluble adenylyl cyclase, 
known as sAC (Kamanetsky et al., 2006).  
The activity of mammalian ACs can be regulated at different levels, such as: at post-translational 
modifications; at the translational level by either covalent modifications or interactions with small 
molecules that stimulate or inhibit AC activity (Table 1.3) or other proteins and at the 
transcriptional level or via mRNA stability (Kamanetsky et al., 2006). sAC, encoded by the 
ADCY10 gene, is sensitive to variation of ATP levels and activated synergistically by calcium and 
bicarbonate (Ho et al, 2010) through decreasing the Km for ATP and increasing sAC’s Vmax, 
respectively (Gancedo, 2013).  
In contrast to sAC modulation, the activity of tmACs is regulated by heterotrimeric G proteins and 
all tmACs are stimulated by the GNAS1 Gsα protein (Table 1.3) (Nicol and Gaspar, 2014; Gancedo, 
2013). Moreover, tmACs can be subclassified according to other regulatory responses, as follows: 
Group 1 (AC1, AC3, AC8) and group 2 (AC5 and AC6) are either stimulated or inhibited by Ca++ 
and calmodulin, respectively; Group 3 (AC2, AC4 and AC7) is stimulated by protein kinase C 
(PKC) and βγ activation; Group (AC9), which is stimulated by βγ subunit and it is calcium 
insensitive; Giα subunits inhibit AC1, AC5 and AC6 (Table 1.3) (Nicol and Gaspar, 2014; Hanoune 
and Defer, 2001).  
The AC isoforms are expressed in many different tissues (Table 1.4) (Sunahara et al, 1996), their 
distinct physiological role and pharmacological properties (Hanoune and Defer, 2001). sAC is 
expressed in various tissues in the cytoplasm, as well as in the mitochondria and in the nuclei cells, 
which reflects the variety of physiological functions, such as: apoptosis, sperm motility, and 
mitochondrial respiration (Gancedo, 2013; Kamenetsky et al., 2006; Hanoune et al., 1997). All 
tmACs are expressed in the CNS, except for AC7 and AC4, where the latter AC has its expression 
restricted to blood vessels in CNS (Table 1.4) (Nicol and Gaspar, 2014; Hanoune and Defer, 2001). 
AC1, AC2 and AC9 seem to be the most abundant in the brain (Hanoune and Defer, 2001).  
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In mammals, AC1 through AC9 are transmembrane proteins that are composed of 1064 to 1353 
amino acids with mass varying from 120-150 kDa (Hanoune et al., 1997). The tmAC structure 
consists of a short N-terminus, two sets of hydrophobic repeats of six transmembrane domains and 
two cytoplasmic catalytic domains (CD1 ad CD2) that heterodimerize to form an active AC (Figure 
1.1) (Kamenetsky et al., 2006). The cytoplasmic regions responsible for the catalytic activity share 
50-70% amino acid sequence identity and the possible site for regulation (Steegborn, 2014; 
Hanoune and Defer, 2001). 
The distinct tissue distribution and structure of tmACs makes it difficult to develop inhibitors to 
target individual ACs. For instance, many studies have focused on a pharmacological approach to 
discover drugs that target AC5, the most abundant isoform in the cardiac tissue, as an alternative 
therapy for heart disease (Vatner et al., 2013; Okumura, et al., 2009). However, it has been difficult 
to identify AC5 inhibitors mainly due to compound membrane impermeability (Ho et al., 2010). 
Therefore, new screens are needed for AC inhibitors that are able to get into cells.  
 
1.8 Use of a fission yeast cell –based platform to study mammalian proteins 
S. pombe and S. cerevisiae are unicellular eukaryotes that possess highly conserved protein-
encoding genes, some of which are homologs to human disease loci (Wood et al., 2012; Wood et 
al., 2002). They are both useful for the expression of biologically-active mammalian proteins. 
Therefore, they have served as important model organisms for the study of many biological 
processes conserved in humans (Demirbas et al., 2011a; Bahler and Wood, 2004; Hayles and Nurse, 
1992). Both yeasts have been used to study PDE genes by cloning and expressing mammalian 
genes to identify and understand mammalian protein function and changes in its activity through 
mutagenesis (Atienza and Colicelli, 1998; Pillai et al., 1993; Nikawa et al., 1987b). This approach 
was used to study the human p53 protein expressed in S. pombe (Bischoff et al., 1992), facilitating 
the isolation of loss of function mutations as a way of understanding the functional domains of this 
protein. In past studies, S. cerevisiae was found to express two PDE proteins, Pde1 (low affinity) 
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and Pde2 (high affinity) enzymes (Nikawa et al., 1987a). In addition, strains carrying deletions of 
both PDE genes, showed increased intracellular cAMP levels, which interfered with the normal 
response to nutrient starvation and conferred heat-shock sensitivity in stationary phase cells 
(Michaeli et al., 1993; Colicelli et al., 1991). Expression of a mammalian PDE gene restored 
resistance to heat shock (Michaeli et al., 1993; Colicelli et al., 1991; Colicelli et a., 1989). 
Moreover, rolipram, prevented the heterologously-expressed PDE4B enzyme from conferring 
survival to heat shock (Pillai et al., 1993). This study demonstrated that regulation of PDE activity 
by specific PDE inhibitors can be assessed in yeast cells. 
 
1.8.1 S. pombe glucose/cAMP signaling pathway 
In unicellular organisms, nutrient sensing mechanisms are important for growth and sexual 
development (Hoffman, 2005b). In both Schizosaccharomyces pombe and Saccharomyces 
cerevisiae, a glucose sensing mechanism promotes a transient cAMP response that activates the 
cAMP-dependent protein kinase (PKA) (Hoffman, 2005). In fission yeast, the glucose/cAMP 
pathway and requires at least seven genes to trigger adenylyl cyclase activation (Hoffman, 2005a; 
Hoffman, 2005b).  
Most of the genes of the S. pombe glucose/ cAMP signaling pathway were identified in a screen 
for mutants that are defective in transcriptional regulation of the fbp1 gene, encoding fructose-1,6-
bisphosphatase (Hoffman and Winston 1990). Growth phenotypes used to identify mutants in the 
cAMP/PKA pathway were conferred by an fbp1-ura4 construct (Hoffman and Winston, 1991), a 
PKA-repressed reporter driving ura4 expression, which produces reciprocal growth patterns on 
media containing 5FOA (5-fluor-orotic acid) or lacking uracil (de Medeiros et al., 2013). Mutations 
that conferred constitutive expression of this reporter affected proteins involved in glucose/cAMP 
signaling (Hoffman and Winston, 1991), such as: Git3 (GPCR) (Welton and Hoffman, 2000), Gpa2 
(Gα subunit) (Landry et al., 2000; Isshiki et al., 1992), Git5 (Gβ subunit) and Git11 (Gγ subunit) 
(Landry and Hoffman, 2001; Landry et al., 2000), Git2/Cyr1 (adenylyl cyclase; Hoffman and 
28 
 
Winston, 1991), Git1 (adenylyl cyclase binding protein) (Kao et al., 2006) and Pka1 (PKA catalytic 
subunit) (Jin et al., 1995). In addition, negative PKA regulators were identified in genetic screens 
for suppressors using this system. For example, a strain carrying a mutation of the cgs2 gene, the 
only fission yeast PDE gene, suppressed an activation-defective form of adenylyl cyclase (git2) 
(Wang et al., 2005). As demonstrated by these studies, the fbp1-ura4 reporter can be used to identify 
mutants that confer growth in medium containing 5FOA or lacking uracil by either stimulating or 
decreasing PKA activity, respectively. The successful use of a PKA repressed reporter in genetic 
screens allowed our lab to develop a platform to screen for small molecule inhibitors of PDEs using 
genetically-engineered strains that express heterologous PDEs in place of the S. pombe Cgs2 PDE 
(Demirbas et al., 2013; Ceyhan et al., 2012; Demirbas et al., 2011; Ivey et al., 2008; Alaamery et 
al., 2010). The fbp1-ura4 reporter was also used to screen for PDE mutants with either altered 
behavior in the presence of PDE inhibitors or altered substrate specificity (de Medeiros et al., 2013). 
While work by our lab and others have generated a collection of selective PDE inhibitors, there is 
a near absence of small molecule PDE activators that can be beneficial as therapeutics and as 
chemical probes to expand our understanding of PDEs’ biological roles. In recent years, our lab has 
developed a new cell-based assay using a GFP reporter that is better-suited for identifying 
compounds that reduce PKA activity, which would include PDE activators or AC and GNAS1 (GαS 
in humans) inhibitors (de Medeiros et al., 2015).  
 
1.9 PKA in S. pombe 
Protein kinase A (PKA) is a serine/threonine kinase that is activated by cAMP (Søberg et al., 2013). 
Once PKA is in its active state it can phosphorylate various proteins, such as: regulatory enzymes, 
ion channels and transcription factors (Gancedo, 2013). PKA activation occurs by binding of cAMP 
to the regulatory subunits (Gancedo, 2013). In mammals, PKA is a heterotetramer comprised of 
two regulatory and two catalytic domains and PKA is inactive in its heterotetrameric form 
(Stratakis, 2012).  
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Table 1.3. Regulation of mammalian AC isoforms and Genome localization 
*Indicates inconclusive data. Table modified from Nicol and Gaspar (2014), Gancedo (2013) and Hanoune 
et al. (1997) 
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Table 1.4. Mammalian AC tissue distribution and biological function* 
 
*Data collected from Hanoune and Defer, 2001. Tissues in bold represent the tissue in which the AC 
isoform has higher expression levels. 
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In S. pombe, the regulatory and catalytic subunits of PKA are encoded by cgs1 and pka1 (Stiefel et 
al., 2004; Hoffman, 2005b). PKA activation occurs when the cAMP pathway produces a cAMP 
response that leads to the binding of cAMP to Cgs1 followed by release of Cgs1 from Pka1 
(Hoffman, 2005b). The use of null mutant alleles involved in cAMP pathway facilitated our 
understanding of the roles of PKA in fission yeast. Studies assessing growth in KCl (Stiefel et al., 
2004), entry into stationary phase and mating have associated these processes with PKA activity 
(Mochizuki and Yamamoto, 1992; DeVoti et al., 1991). Furthermore, Maeda and colleagues (1994) 
reported a delay in spore germination by disruption of pka1+. It was also confirmed that the 
cAMP/PKA signaling pathway regulates spore germination (Hatanaka and Shimoda, 2001).  
Nutritional signaling of glucose via the cAMP pathway represses sexual development in fission 
yeast, as was already mentioned (section 1.8). Deletions of cyr1/git2 (Stiefel et al., 2004; 
Kawakumai et al., 1991), pka1 (Maeda et al., 1994), git3, gpa2, git5, git11, and git1 (Welton and 
Hoffman, 2000; Landry and Hoffman, 2001; Kao and Hoffman, 2006) derepress sexual 
development. In addition, pka1 disruption causes a delay in vegetative growth , but is 
not lethal (Maeda et al., 1994). Conversely, deletions in the cgs2/pde1 inhibit mating and 
stationary phase entry (Mochizuki and Yamamoto, 1992; DeVoti et al., 1991). Furthermore, 
overexpression of the cyr1 gene results in elongated cells with a sterile mating phenotype similarly 
seen in cells expressing high cAMP levels (Kawakumai et al., 1991).  
In S. pombe, the transcription of pka1 and cgs1 are induced under a variety of stress responses 
tested (Chen et al., 2003). In addition, disruption of the git2 adenylyl cyclase gene in yeast cells 
confers KCl-growth sensitivity that is suppressed by mutations in cgs1 that restore PKA activity 
(Stiefel et al., 2004). Finally, in strains expressing the fbp1-ura4 reporter, elevated PKA activity is 
associated with a failure to grow in SC-Ura medium and the ability to grow in 5FOA medium (de 
Medeiros et al., 2013). The phenotypes associated with PKA activity are summarized in Table 1.5.  
 
1.10 Aims of this dissertation 
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This dissertation is comprised of two distinct studies with the objective to expand the tools for the 
understanding of the modulation of the cAMP regulators. In the first study, the aim is to characterize 
a novel dual specificity PDE4/7 inhibitor, previously identified in a screen carried out by our lab. 
To accomplish this goal, I have developed a genetic screen that allowed me to identify mutations 
that confer compound-resistance to PDE genes. In this study, growth in SC-Ura medium (in 
Chapter 3) was used to identify mutations that confer compound resistance to PDE gene (Figure 
1.6): The discovery of PDE4B2 mutant alleles with altered behavior in the presence of dual 
specificity PDE4/7 inhibitor will allow us to understand which amino acids are essential for PDE 
activity and its modulation. The second aim of this study was to develop a chemical screen that can 
identify small molecules that reduce PKA activity by activating PDEs or inhibiting either AC or 
GNAS1. For the second study, I have carried out a 10,000 HTS to detect PDE4D3 activators as a 
proof of concept. Based on the lessons learned from that screen, I carried out a larger HTS using 
two yeast strains that allowed me to target five mammalian proteins. The screening strain expresses 
PDE4D3 and AC5, while the counter-screen strain expresses PDE7B, AC1 and GNAS1. The 
identification of PDE activators and or AC/GNAS1 inhibitors will provide us with new research 
tools to advance our understanding of cAMP-regulated processes and can lead to the development 
of new therapeutics. AC5 or PDE4D3 are enzymes are expressed in various tissues and are seen is 
good drug targets for many diseases like heart and CNS diseases, respectively. 
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Table 1.5. Phenotypes associated with PKA activity 
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Figure 1.6. Phenotypes associated with PKA activity used in the genetic screen. A) Mating occurs 
in the presence of low cAMP levels along with low PKA activity and active PDE enzymes. B) SC-
Ura growth occurs in yeast cells with low cAMP levels and reduced PKA activity. 
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Figure 1.6 Phenotypes associated with PKA activity used in the genetic screen 
A 
 
B 
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CHAPTER TWO 
 
 
MATERIALS AND METHODS 
 
2.1 Materials 
 
2.1.1 Growth Media 
YES-rich medium is as follows: one liter of medium contains 30g of Glucose, 5g of Yeast extract 
and supplemented with required nutrients (Adenine, Histidine, Lysine, Leucine and Uracil) at 225 
mg/L (and 20g agarose for plates). 1M KCl is used for KCl assays. EMM-defined medium is made 
as previously described (Demirbas et al., 2011b). Resistance or sensitivity to PDE inhibitors was 
determined in 5FOA and SC-Ura solid medium as described by Hoffman and Winston (1990). E. 
coli were grown in Luria Bertani (LB) broth (1% tryptone, 0.5% yeast extract and 1% NaCl) with 
ampicillin (100mg/L).  
 
2.1.2 Yeast 
The genotypes of all yeast strains used in this study are listed in Table 2.1. The strains in this thesis 
carried either the fbp1-ura4+ or the fbp1-GFP reporter. Both constructs are translational fusions 
integrated at the fbp1+ locus, as previously described by Hoffman and Winston (1990) and de 
Medeiros et al. (2013), respectively. Strains were grown at 30ºC. 
 
2.1.3 Bacterial strains 
ElectroTen-Blue electroporation competent cells (Agilent Technologies - Stratagene) were used as 
the host strain to amplify plasmids (Invitrogen, San Diego). BL21 (DE3) competent cells (New 
England BioLabs®, Inc.) were used as host strain to express mutant and wild-type PDE4B proteins 
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from the pET15b plasmid for protein purification. Bacterial transformants were selected on LB 
with ampicillin (100mg/L) plates. Cells were grown at 37ºC overnight unless otherwise described.  
 
2.1.4 Enzymes 
Restriction endonuclease enzymes and their buffers were purchased from New England Biolabs 
(NEB, Ipswich, MA) and used according to NEB instructions. The restriction digestion patterns 
were predicted by NEBcutter software. Failsafe enzyme along with Failsafe kit were purchased 
from Epicentre Technologies (Madison, WI). PfuTurbo DNA polymerase was purchased from 
Stratagene (La Jolla, CA) for site-directed mutagenesis PCR.  DNase I (RNase-free) was purchased 
from New England BioLabs Inc. (Ipswich, MA) and used for protein purification. 
 
2.1.5 Buffers for protein purification 
 
2.1.5.1 Buffers for protein purification using Affinity column 
Affinity-purification of his-tagged proteins was carried out using Talon beads by Clontech 
(Mountain View, CA). The sonicate buffer was at a 50mL final concentration 0.004 mg/mL stocks 
of leupeptin and aprotinin each, 10mg of 1 mg/mL lysozyme, 10% glycerol, PMSF 0.01M and 
0.1% DNase I (RNase free) and 0.2% Triton-x100 filled with modified Buffer A (described in 
2.1.5.2 section). The binding buffer was a modified Buffer A (described in section 2.1.5.2) without 
imidazole. The elution buffer was prepared with 10 mL of 20 mM Tris-HCl, pH 7.5, 50 mM NaCl, 
0.4 M imidazole and 1mM ME was used for protein elution.  
 
2.1.5.2 Buffers for protein purification using Ion-Exchange column 
The Ion-exchange column used was a Q-Sepharose column by GE Healthcare Sciences 
(Marlborough, MA). The buffers were prepared as followed: Buffer A was prepared to a 500 mL 
final volume with 20 mM Tris-HCl, pH 7.5, 20 mM Imidazole, 300 mM NaCl, 1 mM ME; Buffer 
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B, only differ from Buffer A with the following reagents: 50 mM NaCl, 1mM ME. Buffers C1, 
C2, C3 and C5 contained 20 mM Tris-HCl, pH 7.5, 1 mM EDTA, 1mM ME with varying final 
concentrations of NaCl (100 mM, 200 mM, 300 mM, 500 mM, respectively). 
 
2.1.6 Antibodies 
For the immunodetection, the primary antibody (rabbit polyclonal IgG, a His probe, sc-803-G) and 
the secondary antibody (goat anti-rabbit IgG-HRP, sc-2004) were purchased from Santa Cruz 
(Dallas, TX) and used in 1:500 and 1:1500 dilutions, respectively.  
 
2.1.7 Small molecules used in counterscreens and cAMP assays 
Small molecules were purchased from ChemDiv, IFLab2, Enamine and Maybridge. 20mM stocks 
were prepared by dissolving the small molecules in DMSO and storing at -80ºC. 
 
2.2 Methods  
2.2.1 Strain mating and tetrad dissection 
Yeast strains were patched onto YES solid medium prior to mating. The freshly streaked strains 
were mated on EMM solid medium for 24 h at 30ºC. After that, asci were separated and dissected 
using a dissection needle to YES plate. After germination and colony formation, progeny was 
scored by replica plating to selective medium. In some cases, whole cell PCR was carried out to 
confirm what AC or PDE was present in the progeny for crosses. 
 
2.2.2 Mutagenic PCR 
Mutagenesis PCR was performed to clone either the mammalian PDE4B2 (Genbank accession 
number L20971) or PDE7B1 (Genbank accession number NM_018945) by flanking 
Schizosaccharomyces pombe cgs2 gene sequence. PCR products were generated by FailSafe PCR 
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kit using “Premix" buffers B, C, J and L (Epicentre Biotechnologies, Madison, WI) to increase 
mutations (Clontech, 2001). The custom DNA primers ordered from Integrated DNA Technologies 
(Coralville, IA) were the following: cgsmut5’ (5’TCATAGCATA-CTTCTTCACCAAGC3’) and 
cgsmut3’ (3’AAAGTGTCCGATGAGAAAAGCGTG). FailSafe PCR kit used for Mutagenic PCR 
system was optimized to 20 cycles to decrease the number of mutations per clone and to increase 
the chances in targeting single amino acid substitutions to produce phenotypic changes. The PCR 
products containing PDE4B2 or PDE7B1 were co-transformed into StuI-linearized plasmid pKG3-
dropout vector (Hoffman lab, unpublished) by gap-repair DMSO transformation protocol (Bahler 
et al., 1998) followed by a genetic screen, described in 2.2.5 section. Plasmids pKG3-PDE4B2 or 
pKG3-PDE7B1 were transformed in yeast strains as a control. PCR products were verified by gel 
electrophoresis. 
 
2.2.3 Genetic screens 
A genetic screen was developed in the present study to identify and isolate BC54 compound-
resistant PDE4B2 alleles by their ability to confer growth on SC-Ura plates in the presence of 
BC54. (BC54 inhibits PDE4B2 to elevate cAMP-levels and repress fbp1-ura4 expression, thus 
preventing growth on SC-Ura medium.) After mutagenic PCR and gap-repair transformation of 
strain CHP1346, the PDE4B2-expressing transformants cultured from EMM-Leu plates were 
collected in 10mL in water, resuspended in 1 mL of 15% glycerol and stored at -80ºC to allow for 
screening of individual pools of transformants. The screening steps were as follows: 
1.  Generate a pool of transformants by PCR; 
2. Collect pools of transformants and make frozen stocks for subsequent screening; 
3. Transfer aliquot of frozen transformants to 10mL of EMM-Leu liquid medium on a rotating 
wheel overnight at 30 ⁰C; 
4.  Thaw an aliquot of transformants, dilute 10-fold in 4mL EMM-Leu liquid medium and 
incubate for 6-8 hours on a rotating wheel at 30 ⁰C; 
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5. Transfer 5 x 105 cells into an eppendorf tube and pellet by microcentrifugation (5 seconds); 
6. Enrich for cells that are able to enter stationary phase by resuspending cells in 100µL YES 
medium with 10µM BC54 and incubating for 3 days without shaking at 30 ⁰C to allow cells to 
grow to stationary phase; 
7. Dilute samples 10-fold and count live cells; 
8. Repeat enrichment steps 4 to 6 two more times; 
9. Transfer 50 µL of 10-fold diluted samples to 100 µL of sterile distilled water and spread onto 
EMM-Leu plates to select for cells with candidate plasmids; 
10. Collect cells from EMM-Leu and plate 5 x 105 transformants onto SC-ura plates in the presence 
of 10mM BC54. Incubate at 30ºC for three days; 
11. Rescue plasmids from colonies that form in the zone of inhibition and transform E. coli for 
plasmid preps. 
12. Sequence PDE4B allele in plasmid candidates; 
13. Re-test purified candidate transformants on SC-ura plate containing a spot of BC54 for final 
assessment. 
 
Candidate plasmids were rescued out of yeast into E. coli as previously described (Hoffman and 
Winston, 1987) and were sent out for sequencing.  Upon confirmation of mutations, mutant 
plasmids were digested for linearization before integration. Both mutant plasmids were incubated 
overnight in YES liquid medium for integration to the chromosome and plated in 5FOA medium 
to confirm mutant PDE4B was replaced a copy of ura4 in the cgs2 locus. Following confirmation, 
mating phenotype was assessed by iodine stain for 2 minutes and strains were constructed that 
express PDE4B2Y233H or PDE4B2T407A in combination with either the fbp1-ura4 or fbp1-GFP 
reporter for further validation of compound resistant phenotype with cell-based assays (Table 2.1). 
A schematic for the genetic screen is depicted in Figure 2.1. 
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2.2.4 Cloning and Plasmid construction 
Mutant plasmid candidates were rescued out of yeast into E. coli by using the Smash and Grab 
method (Hoffman and Winston, 1987) and sent out for sequencing. After sequencing, plasmids 
containing candidate alleles PDE4B2T407 and PDE4B2Y233H were integrated into the chromosome 
of S. pombe CHP1662, replacing the ura4+ gene that was inserted into the cgs2 locus. 
Once integrated, these mutant alleles were combined with either the fbp1-ura4 or fbp1-GFP 
reporter by traditional yeast crosses. These strains also carried the git2∆ that prevents endogenous 
cAMP production so as to allow for the characterization mutant PDE4B2 activity in strains exposed 
to varying levels of exogenous cAMP or cGMP. 
 
2.2.5 DNA sequencing 
The purified plasmids were sent out to Eurofins MWG Operon (Huntsville, Alabama) for DNA 
sequencing and confirmation of base-pair change. The following primers were used to amplify the 
mutant candidate gene: PDE4BAMPF (ATATTCCAGGAAAGAGACCTCC) and, 1157R (5’ 
TTGCGAAGGACCTGAATGCG3’). The PDE4BAMPF primer was also used for the sequencing 
analysis of the site-directed mutagenesis products. 
 
2.2.6 Cell-based assays 
Plasmids were integrated into strains as described in the previous section to assess if these 
mutations were responsible for the altered behavior in the presence of BC54 (PDE4B inhibitor) in 
two cell-based assays.  
 
2.2.6.1 5FOA assays  
This cell-based platform is a counterselectable assay used to study genetically engineered strains 
expressing mammalian PDEs and carrying the fbp1-ura4 reporter. In these strains, the fbp1 
promoter drives the expression of the ura4 gene. When the fbp1 promoter is derepressed as is the 
42 
 
case when PKA activity is low, yeast cells fail to grow in 5-fluoorotic acid (5FOA) medium 
(Demirbas et al., 2011a; Demirbas et al., 2011b). Compounds that reduce PDE activity to increase 
cNMP levels to activate PKA can be detected by their ability to confer 5FOA-resistant growth 
(Figure 2.2a). For this assay, cells must be grown under conditions that lead to the repression of the 
fbp1-ura4 reporter prior to their transfer to 5FOA medium (Table 2.2).  
 
2.2.6.2 GFP assays 
This cell-based platform was used as another method to assess either PDE or AC activity in 
genetically engineered strains carrying the fbp1-GFP reporter (Figure 2.2b). The activity of these 
enzymes could be tested for mutant PDEs in the presence of an inhibitor, PDE activators or AC 
inhibitors, as previously described (de Medeiros et al., 2015). The enzymatic activity of PDE was 
correlated with the levels of GFP signal, which was normalized by OD600 to decrease well-to well 
variation. Growth conditions were determined for the pre-growth steps to shut off of the GFP 
reporter and proper assessment of small molecules (Table 2.3). 
 
2.2.7 Site directed mutagenesis 
The mutants were generated as described by QuickChange II site-directed mutagenesis kit from 
Agilent Technologies (Santa Clara, CA). The PCR method was performed on pET15b vector 
expressing wild-type PDE4B catalytic domain (acquired from Dr. Hengming Ke) to generate the 
mutant PDE4B alleles by using the following primers: T407-F (5’AATTGTACGGCAATGG-
GCAGACCGCATCATGGAGGA3’), T407-R (5’TCCTCCATGATGCGGTCTGCCCATTGCC-
GATACAATT3’), Y233H-F (5’CCATTCTGACGTGGCACATCACAACAGCCTGAC3’), and 
Y233H-R (5’GTGCAGGCTGTTGTGATGTGCCACGTCAGAATGG3’). The products were 
confirmed by DNA sequencing. 
 
2.2.8 Protein purification 
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Table 2.1. Yeast strain list used in this study 
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Figure 2.1. Development of a genetic screen. A) Gap repair was performed to clone candidate 
mutant alleles of PDE4B generated by PCR into the plasmid. B) Genetic screen protocol. C) 
Microscopic examination of cells in stationary phase in the presence (left) or absence (right) of 
compound BC54. Inhibition of PDE4B in these cells confers a rapid loss of viability in stationary 
phase. 
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Figure 2.1 Development of a genetic screen  
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E. coli competent cells carrying pEt15b vector, expressing the catalytic domain of either wild-type  
or mutant proteins, were grown in 100 mL LB medium batch with 0.1 g/mL ampicillin resistance 
overnight. The cultures were (1:90 fold) diluted to 900mL LB medium and 0.1 g/mL ampicillin 
and grown for at 37ºC for 2-3 hours. OD’s were targeted to 0.6-0.7 absorbance for induction using 
IPTG (0.2 mM, as the final concentration) at 16ºC for 18-20 hours. Induced samples were 
centrifuged down in 85mL Nalgene tubes at 8500 rpm for 10 minutes at 4ₒC. Pellets were 
resuspended in sonication buffer and incubated on ice for 30 minutes and sonicated 3 times for 30 
seconds with intervals of 10 seconds followed by centrifugation for 30 minutes at85000rpm twice. 
A cobalt column was chosen for the affinity purification since the proteins studied carry a 6-His 
tag (attached to N- terminus of the protein). The Talon® Metal affinity resins manual from Clontech 
Laboratories, Inc (Mountain View, CA) was used for affinity chromatography with the following 
modifications:  4mL of beads (per culture) were suspended and washed once with 10mL Sonicate 
buffer. Next, supernatant samples were transferred and incubated with talon beads in a shaker at 
4ₒC for 3.5 hours or overnight, PDE4Bwt and PDE4T407A or PDE4BY233H sample, respectively for 
binding. After that, samples were flown under gravity and eluted by 12 mL of elution buffer. In 
each step of the procedure, aliquots were collected to confirm purification by SDS-PAGE and 
Western blot analysis. For further purification (removal of elution buffer), an Ion – exchange 
chromatography was performed with Q-Sepharose column using 2mL Q-beads washed with 10 mL 
buffer B twice. After that, samples were loaded, flowed under gravity and washed with 10mL 
Buffer C1.  Flow through was collected in every step. Samples were eluted with 4.5 mL buffers 
C2, C3, C5 in 1.5 mL fractions. Purified proteins sizes were confirmed by SDS- PAGE and Western 
blot analysis. Commassie blue was used to detect proteins. Precision Plus PorinteTM Kaleidoscope 
from Bio-rad was used as the protein standard ladder. After that, centrifugation was performed 
using Amicon ultra-15 for protein concentration according to manufacture specifications (EMD 
Millipore) and aliquoted into -80ºC freezer. 
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2.2.9 In vitro assays 
In vitro enzyme assays were performed using the barium precipitation method as previously 
described (Wang et al, 2005a). In this method, samples are incubated in a heating block set at25⁰C. 
Reactions are stopped with a final concentration of 0.2M of ZnSo4 (Zinc sulfate) and, after that 
final concentration of 0.25N Ba(OH)2 (Barium hydroxide) is added to precipitate the product. 
Samples are centrifuged in a microcentrifuged at maximum speed for 15 minutes and supernatant 
is collected for analyses. The amount of product produced during the reaction was estimated as: 
(CT- CO)/CT, where CT represents cpm at time (without enzyme) and CO represents the starting cpm. 
The activity of recombinant human PDE4B2 enzyme and its mutant forms (Y233H and T407A) 
were tested as followed: To calculate the Vmax of PDE4WT and mutant proteins, the assay was 
saturated with 10µM of cold substrate (cAMP). To investigate the enzymatic activity of these 
proteins, in vitro assays were performed to measure enzyme efficiency (Wang et al., 2007) and IC50 
assays (by Ceyhan et al., 2012). The IC50 was estimated as the concentration of BC54 or Rolipram 
that reduced enzyme activity by 50%. The substrate concentration of 0.5 µM was used for both 
enzymes based on a Km of 5µM for PDE4B2, as previously described (Beavo and Conti, 2007). 
Reactions proceeded for 25 and 40 minutes for PDE4B2 wild-type and T407 mutant, respectively, 
during which time in the production of product was linear with time. The amount of hydrolysis was 
generally limited between 42-50% and the IC50 values were calculated from the means of at least 
three independent experiments. Substrate concentration was ≤ 0.1 Km for each enzyme with IC50 
values representing approximate the inhibitor Ki values. 
 
 2.2.10 Protein Measurements 
Purified enzyme concentrations were determined using BCA assays according to manufacturer’s 
protocol (Pierce in Rockford, IL). 
 
2.2.11 High-throughput screens (HTS) 
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2.2.11.1 10,000 HTS for PDE activators 
High-throughput chemical screens were performed at the ICCB facility at Harvard Medical School. 
Prior to the screening, a collection of strains was created expressing the short and long forms of 
mammalian PDE4D proteins. After that, the optimal cell density was determined by detecting the 
basal GFP signals of a PDE-expressing strain in comparison to a strain not expressing PDE (de 
Medeiros et al., 2015). This allows for the proper assessment of a compound that reduces PKA 
activity. The strains used were CHP1702 (expressing PDE4D3), our experimental sample, and 
strain CHP1742 (expressing PDE4D2) (Table 2.1). Strain CHP1702 expresses the PDE4D3 long 
form that has a PKA autoregulatory domain and strain CHP1742, the PDE4D2 short form, was 
used as the genetic mimic of a positive control due to lack of known PDE4D activators. A PDE4D2 
lacks the inhibitory domain present in PDE4D3, it displays a higher PDE activity and higher GFP 
values, similar to what a PDE activator might confer upon the screening strain. Once the screening 
conditions were optimized using a 384-well microtiter dish with black walls and clear bottom to 
measure GFP signals. Finally, the optimal cell concentration for each strain was determined for 
inoculation in the microtiter dishes in other to produce a Z-factor > 0.5 (see below) as a reflection 
of the HTS quality. The starting cell concentrations used are seen in Table 2.3. For this HTS, strains 
were pre-grown to exponential phase in EMM complete medium without or with 20mM cAMP 
overnight (CHP1742) and cells were prepared for pinning of compounds, as previously described 
(de Medeiros et al., 2015). The stock solutions of compounds tested were generally 5mg/mL with 
the exception of ChemDiv6 where compounds are 10mM. Plates were incubated in a container with 
“moist” paper towel to prevent evaporation for 48h at 30ºC. GFP fluorescence and optical densities 
(OD600) of cultures were measured using an Envision plate reader, with a 485 eGFP excitation filter 
and 535 eGFP emission filter and 485 filters and 505 mirror for OD bottom readings. GFP values 
were normalized by OD values to decrease well-to-well variation. 
Compounds hits for the 10,000 HTS were determined by Z-scores of the experimental wells that 
were calculated using the mean and standard deviation of the negative controls for each plate (cells  
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Table 2.2. Optimal growth conditions used in 5FOA assays 
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Figure 2.2. Basis for secondary screen. A) Basis for 5FOA assay. When cAMP levels are low, 
the fbp1 promoter is derepressed and the ura4 gene is expressed (left). In the presence of a PDE4B 
inhibitor, cAMP levels increase, the fbp1 promoter is repressed, and ura4 is not expressed (right) 
resulting in 5FOA-resistant growth. B) Basis for GFP assay. Reduction of PKA activity by either 
PDE activator or AC/GNAS1, decrease cAMP levels followed by detection of GFP signal (left). 
Increase in PKA activity by PDE inhibition or AC activation, increases cAMP levels increase and 
reduce GFP signal (right). 
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Figure 2.2 Basis for secondary screen 
A 
 
B 
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Table 2.3. Optimal growth conditions used in GFP assays 
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growing in DMSO) as described previously (Ceyhan et al., 2012). Cherry pick was performed as 
using pocket tips. Bioinformatic analyses were performed using the Vortex Software provided by 
ICCB. Cherrypicked compounds were retested in 75uM concentration to validate the hits using 
strains CHP1702 (PDE4D3), CHP1807 (PDE4D3 and AC4) and CHP1812 (AC4). Counter-screen 
assays were performed for further validation and characterization of final candidate PDE4D3  
activators. 
 
2.2.11.2 HTS for PDE activators  
After the 10,000 HTS was concluded, a collection of strains was created expressing a combination 
of mammalian AC and PDE proteins for a larger HTS for compounds that reduce PKA activity as 
previously mentioned in section 2.2.12.1. In this HTS, we chose strains CHP1823 (expressing 
PDE4D3 and AC5), CHP1882 and CHP1883 (expressing PDE7B1 and PDE4D2) that expressed 
similar basal GFP signals for our experimental sample and counter-screen strains, respectively, 
along with strain CHP1742 (expressing PDE4D2) as the genetic positive control (Table 2.1). Strain 
CHP1823 expresses the long form PDE4D3 protein that has a PKA regulated autoinhibitory 
domain. As there are no known small molecule activators of PDE4 enzymes, strain CHP1742, 
which expresses the PDE4D2 short form, was used as the genetic positive control that produces a 
high GFP value due to high PDE4 activity. The initial counter-screen strain CHP1883 was 
substituted by strain CHP1882 that has the same genotype, but display a better growth behavior, 
which facilitated the elimination of false positive compounds. Finally, the optimal cell 
concentration for each strain was determined for inoculation in the microtiter dishes in other to 
produce a Z-factor > 0.5 (see below) as a reflection of the HTS quality. The starting cell 
concentrations used are seen in Table 2.3. For this HTS, strains were pre-grown to exponential 
phase in EMM complete medium without or with 20mM cAMP overnight (CHP1742) and 
procedure was performed as previously described (de Medeiros et al., 2015). The stock solutions 
of compounds tested were generally 5mg/mL with the exception of ChemDiv6 library where 
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compounds were stored at 10 mM. Plates were incubated in a container with “moist” paper towel 
to prevent evaporation for 48h at 30ₒC. Prior to readings, plates were vortexed with a plate mixer 
to prevent clumping 90 minutes before data collection. GFP fluorescence and optical densities 
(OD600) of cultures were measured using an Envision plate reader, using 485 eGFP excitation filter 
and 535 eGFP emission filter and 485 filters and 505 mirror for OD bottom readings. Compounds 
hits for the 100,000 HTS were chosen by analyzing median and mean absolute deviation (MAD) 
of the experimental samples for each plate in order to assign Z-scores to each well. This approach 
takes into consideration the variation within treated samples and is more practical than using mean 
and standard deviation of negative controls. Z-scores were calculated by subtracting the median 
value of the normalized GFP values for the experimental samples in a plate from the value of each 
individual well and dividing this by the MAD value for each plate (MADs were generally ~4-7% 
of the median). In addition, a differential Z-score was calculated by addition of Z-scores from the 
duplicate experimental or counter-screen strains followed by subtraction of the former to the latter. 
Compounds that produced OD600 values of < 0.6 were excluded as being toxic. Bioinformatics 
analyses were performed using the Vortex Software provided by ICCB. Cherry picked compounds 
were retested in a dose-dependent manner (from 0.675uM to 5uM) to validate the hits against 
PDE4D3 – and AC1- expressing strain (CHP1805), PDE7B1- and AC5- expressing strain 
(CHP1822), PDE4D3- and AC5- expressing strain (CHP1823) and PDE7B1- and AC6- expressing 
strain (CHP2028). Counter-screen assays were performed for further validation and 
characterization of final candidates in terms of specificity to either PDE4D3 or AC5. 
 
2.2.12 cAMP assays 
Cells were treated with small molecules at a final concentration of 20 µM for 1 and a half hours in 
the rotating wheel at 30ₒC and collected by filtration onto glass filters (Fisher). Filters were 
incubated in 1mL of 1M formic acid for 20 minutes and filters were removed and samples were 
evaporated in a Speedvac as previously described (Byrne and Hoffman, 1993). After that, pellets 
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were resuspended in the same volume of 0.1 HCl and assayed using cAMP Direct Kit according to 
Enzo Life Sciences specifications. 
 
2.2.13 KCl assays 
Yeast strains were pre-cultured in YES medium and transferred to YES with 1M KCl to assess 
KCl-resistance. The initial cell concentration of all strains tested in KCl assays was 2 x 105 
cells/mL. After that, a 2.5-fold serial dilution (from 20µM to 1.28µM) of candidate PDE4D 
activators or AC5 inhibitors was performed to determine whether the compounds affected the 
activity of either enzyme.  
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CHAPTER THREE 
IDENTIFICATION AND CHARACTERIZATION OF 
COMPOUND RESISTANT ALLELES OF PDE4B TO DUAL 
PDE4/7 INHIBITOR BC54 
 
3.1 Development of a S. pombe genetic screen for compound – resistant alleles of PDE genes 
This chapter describes the development of and results from a fission yeast genetic screen to identify 
mutant PDE4 and PDE7 alleles that have altered sensitivity to compounds previously identified in 
our lab, including BC54, a potent inhibitor of both PDE4 and PDE7 enzymes.  
 
3.1.1 Discovery of a dual specificity PDE4/7 inhibitor 
Previously, the Hoffman lab constructed a collection of strains in which mammalian PDEs replaced 
the cgs2/pde1 (Demirbas et al., 2011a) and have used the strains to identify small molecule 
inhibitors of the mammalian PDEs. Our lab has taken advantage of the fbp1-ura4 reporter, a PKA 
repressed reporter, to develop HTS for small molecules that can be detected by their ability to 
increase PKA activity (Demirbas et al., 2013; Ceyhan et al., 2012; Alaamery et al., 2010; Ivey et 
al., 2008). Thus, the Hoffman lab has identified a collection of PDE inhibitors. One of these 
compounds, BC54, is a small molecule that has a dual specificity role of inhibiting both PDE4 and 
PDE7 enzymes (Figure 3.1) (Demirbas et al., 2011a). 
BC54 has been tested in different assays discussed further in this chapter. In the cell-based assay 
for 5FOA-resistant growth, BC54 is a potent inhibitor of both PDE4 and PDE7 enzymes as seen 
by its ability to confer 5FOAR growth to strains expressing PDE4B2 (CHP1268) and PDE7B 
(CHP1209) (Figure 3.2a). In addition, treatment of strain expressing PDE4B2 (CHP1268) with 
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BC54 seemed as potent as rolipram treatment (Figure 3.2b). After that, we decided to develop a 
genetic screen to identify mutations in PDE genes that would confer resistance to a specific 
inhibitor as a way of learning more about the interactions of these compounds with their target 
proteins, as this information could help guide future efforts to design more effect derivatives of 
these compounds.  
The assay development involved 3 steps: (1) To select the strain that can differentiate cell survival 
in the presence of PDE4/7 inhibitors; (2) To develop enrichment conditions to increase cell viability 
in the presence PDE4/7 inhibitors; (3) To optimize the conditions to assess growth in SC-ura 
medium. 
 
3.1.2 Cell survival test 
Failure to enter stationary phase is associated with high PKA activity (DeVoti et al., 1991).  
Therefore, cells lacking PDE activity rapidly die in a saturated culture. This could then allow one 
to selectively enrich a population of cells for those that retain PDE activity in the presence of a 
PDE inhibitor. The following experiment was carried out to test our ability to selectively kill off 
cells with different levels of PKA activity. Six different strains carrying various combinations of 
mutations involved in cAMP metabolism were chosen. The summary of the strains genotypes and 
cAMP production and/ or PDE activity are listed in Table 3.1.  
The cell survival phenotype was assessed by both microscopy and spot plating. The 100-fold 
diluted cultures were prepared as described (section 2.2.3). The percentage of live and dead cells 
were counted under the microscope after each round of enrichment (data not shown). This step will 
be discussed in more detail (section 3.1.3). 
Spot plating was performed as followed: a four serial dilution of an initial 100-fold diluted culture 
was performed and spotted on YES plate using an initial culture concentration of 5 x 105 cells/ mL. 
Each dilution was a 10-fold dilution of the previous dilution. After incubation, cell survival was 
scored by counting the number of colony-forming units from the most diluted sample. The 
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transformant strain that produced cAMP and expressed PDE4B2 (CHP1346) had a 10-fold 
reduction in survival in the presence of PDE4 or PDE7 inhibitors in comparison to strain not treated 
with such compound (Figure 3.3), consistent with the idea that PDE inhibition would elevate PKA 
activity and reduce cell viability in stationary phase. 
 
3.1.3 Optimization of enrichment conditions 
The purpose of the enrichment is to increase the percentage of transformants that can survive in the 
presence of the inhibitors due to the expression of a compound resistance PDE alleles. The details 
for the enrichment are provided in Chapter 2. The optimal concentration of inhibitor is 10 µM, 
which allows cell survival of the mutants under conditions that would inhibit stationary phase entry 
and otherwise kill most of the cells. In addition, mutant cell survival must be higher than wild-type 
cell survival. The number of cells used allowed for growth in the absence of inhibitors and for 
proper assessment of strain expressing wild-type PDE4 and PDE7 enzymes in the presence of their 
respective inhibitors (Figure 3.4). Thus, compound resistant transformants are expected to grow in 
the zone of inhibition (Figure 3.5). The zone of inhibition is formed after the compound is added 
directly to the center of the plate and the compound diffuses during incubation. 
 
3.1.4 Screening 
The screening strain (CHP1346) carries a frameshift mutation in the cgs2 gene and, consequently 
has no PDE activity (Table 2.1). In addition, CHP1346 has the wild-type git2 gene that encodes 
adenylyl cyclase. Therefore, CHP1346 strain produces its own cAMP. In addition, cells lacking 
PDE activity have a faster loss of survival, which allows for enrichment of cells surviving in the 
presence of compounds (de Medeiros et al., 2013). In order to generate PDE4B and PDE7B mutant 
alleles, a random mutagenic PCR was performed and PDE4B and PDE7B PCR products were 
cloned by gap repair into the pKG3 plasmid (Figure 2.1) so as to place these PDE ORFs under the 
control of the cgs2 promoter. Pools of PCR products were cloned by gap repair into strain CHP1346 
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(Table 2.1), as previously described (section 2.2.2), and mutant PDE4B and PDE7B transformants 
were enriched as described in section 2.2.3. After enrichment, transformant cells were cultured in 
solid media (EMM-Leu and SC-Ura) in the presence of BC54 (section 2.2.3). Seven mutants for 
each PDE4B and PDE7B allele candidates were isolated after screening for survival in stationary 
phase in the presence of the inhibitor and sent for sequencing. Upon sequencing analysis, two 
candidate alleles were identified. The PDE4B mutants had either Y233H or T407A altered residues 
located near the cAMP-binding pocket that could interact directly with the adenosine of cAMP 
(Figure 3.6). Each mutant allele expressed in plasmid was integrated into the chromosome of 
CHP1662 strain (Table 2.1) by replacing the cgs2::ura4+ marker. After that, mutant alleles were 
selected for in 5FOA – resistant transformants. Strains were constructed that express PDE4B2Y233H 
or PDE4B2T407A in combination with either the fbp1-ura4 or fbp1-GFP reporter (Table 2.2) for 
further characterization using cell-based assays. 
 
3.2 Characterization of mutant PDE4B strains in 5FOA assays 
In order to reconfirm the compound resistant PDE4B phenotype, I used the following approach: 
mutant PDE4B strains were characterized by 5FOA growth assays in response to varying doses of 
BC54 (Figure 2.2a). The strains used in this cell-based assay have a deletion of the git2 adenylyl 
cyclase gene, which allows for the regulation of the fbp1-ura4 reporter expression by exogenous 
cAMP added to the 5FOA medium. Prior to the 5FOA assay, a cAMP growth curve was carried 
out (data not shown) to assess the hydrolytic activity of the candidate mutant PDEs and identify 
conditions for detecting compound sensitivity. Pre-growth conditions are described in Table 2.2. 
After that, 5FOA assays were performed in the presence of either BC54 or rolipram, a well-known  
PDE4 inhibitor. The growth of the strain expressing wild-type PDE4B (WTPDE4B) in 5FOA 
medium represents sensitivity to BC54 (Figure 3.7a) and rolipram (Figure 3.7b). Both PDE4B2T407A 
and PDE4B2Y233H are resistant to BC54 (Figure 3.7a) and rolipram (Figure 3.7b) in comparison to 
strain expressing WTPDE4B, as seen by the inability of these compounds to confer 
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Figure 3.1. Structure of dual specificity PDE4/7 inhibitor (BC54).  BC54, (ethyl (2Z)–2–
(acetylimino)-1-cyclohexyl-5-oxo-1,5-dihydro-3H-dipyrido{1,2-a:2’,3’-d]pyrimidine-3-
carboxylate, was identified from the ChemDiv 3 library in screens carried out at the Broad Institute 
Screening Facility. 
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Figure 3.1 Structure of dual specificity PDE4/7 inhibitor (BC54) 
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Figure 3.2. 5FOA growth assays of strain expressing wild type PDE4B2 or wild-type PDE7B. A) 
Growth treatment of strains (PDE7B and PDE4B) in the presence of BC54. B) Growth treatment 
of strain expressing PDE4B2 (CHP1268) in the presence of either BC54 or rolipram. Values 
represent the average of OD600 ± standard error from three independent experiments. The values 
within each experiment represent an average of four replicate wells. Each experiment was 
incubated for a 48h growth at 30ₒC. 
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Figure 3.2 5FOA growth assays of strain expressing wild type PDE4B2 or wild-type PDE7B 
 
A                                              B 
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Table 3.1. Strains used for cell survival test 
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5FOAR growth. 
 
3.3 Characterization of mutant PDE4B strain in GFP assays 
The compound-resistant nature of these mutant PDE4B alleles was also confirmed independently 
via GFP assays (Figure 3.9a, b). Prior to the GFP assay, a cAMP curve for a GFP assay was 
performed to assess the hydrolytic activity of the candidate mutant strains, PDE4B2Y233H, 
PDE4B2T407A and wild-type PDE4B2 (Figure 3.8). In addition, the cAMP curve is used to identify 
conditions for measuring compound sensitivity, such as the concentration of cAMP that would 
repress GFP expression in a strain lacking PDE activity, but not in strains expressing these PDE4 
enzymes. 
The concentration of exogenous cAMP needed to activate PKA to repress fbp1-GFP reporter 
expression reflects PDE activity (Figure 2.2b), as previously described (section 2.2.6.2; more 
cAMP is required in the presence of an active PDE. In this cAMP curve, the addition of 1.5 mM 
cAMP was found to be optimal for pre-culture conditions, promoting cell growth while repressing 
fbp1-GFP reporter and keeping the PDE activity low (Figure 3.8). The exogenous cAMP 
concentration of 0.25 mM was used for assessment of strains in the presence of inhibitors (Table 
2.3). PDE4B2T407A strain (CHP1712) hydrolyzed more cAMP than the PDE4Bwt strain (CHP1641) 
(Figure 3.8). However, the mutant PDE4BY233H strain (CHP1679) hydrolyzed less cAMP than the 
PDE4Bwt strain (Figure 3.8), which supports growth observations that this mutant expresses a weak 
PDE enzyme. After that, GFP assays were performed in the presence of either BC54 or rolipram. 
In this assay, the inhibition of PDE activity leads to a reduction in fluorescence, which corresponds 
to sensitivity to BC54 and rolipram (Figure 3.9a, b). The reduction of GFP values in the treatment 
of PDE4Bwt strain (CHP1641) with either BC54 (Figure 3.9a) or rolipram (Figure 3.9b) confirms 
the wild-type PDE4B strain sensitivity to both compounds. In addition, BC54 is much more 
effective on wild type PDE4B than is rolipram. The mutant PDE4BT407A strain (CHP1712) has a 
partial altered behavior consistent to its lower sensitivity to BC54 (Figure 3.9a). The mutant  
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Figure 3.3. Stationary cell survival. Host strain producing cAMP and expressing PDE activity has 
a 10-fold survival reduction in the presence of PDE inhibitor. Cell survival is not affected if the 
host strain does not produce cAMP or does not express a PDE. The culture with initial cell 
concentration of 5 x 105 cells/ mL was diluted 100-fold, followed by four series of a 10-fold 
dilutions and spotted on YES plate. YES plates were incubated for 3 days at 30⁰C. 
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Figure 3.3 Stationary cell survival 
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Figure 3.4. Inhibition of growth by PDE inhibitors in SC-ura. Growth phenotype of strains 
expressing either PDE7B (top) or PDE4B (bottom) in SC-ura medium. Growth is due to PDE 
activity that reduces PKA activity to allow fbp1-ura4 expression and is unaffected by DMSO (the 
vehicle for the compounds). The PDE inhibition prevents growth by activating PKA in the presence 
of family-specific inhibitor or dual PDE7B/4B inhibitor. Such growth inhibition should allow us to 
screen for compound–resistant alleles that promote growth in inhibition zone. Compounds are 
directly delivered to the plate. Four spots for compounds were formed in each plate. 
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Figure 3.4 Inhibition of growth by PDE inhibitors in SC-ura  
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Figure 3.5. Mutant PDE4B alleles display growth in a halo assay in SC-ura. Growth phenotype of 
transformants expressing either wild type PDE4B (left), PDE4BT407 (middle) or PDE4BY233H (right) 
in SC-ura medium. Approximately 5 x 105 transformants are spread onto an SC-ura plate onto 
which BC54 was directly delivered to the center of the plate on one single spot. Growth is due to 
compound- resistance phenotype that reduces PKA activity to allow fbp1-ura4 expression. SC- ura 
plates with transformants expressing either wild type PDE4B or PDE4BT407 were incubated for 4 
days. SC- ura plate with transformant expressing PDE4BY233H was incubated for 7 days. 
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Figure 3.5 Mutant PDE4B alleles display growth in a halo assay in SC-ura 
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Figure 3.6. Crystal structure of PDE4D bound to cAMP (PDB: 2PW3: Ke et al., 2008). The crystal 
structure highlights altered residues of PDE4B, threonine (T) in red and Tyrosine (Y) in yellow, in 
close proximity to cAMP. There is no crystal structure of PDE4B bound to cAMP. For this reason, 
PDE4D crystal structure was used. The PDE4D bound to cAMP crystal structure was displayed 
and modified using PyMOL software. 
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Figure 3.6 Crystal structure of PDE4D bound to cAMP 
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PDE4BT407A strain has an altered behavior consistent to its partial resistance to rolipram in 
comparison to wild-type PDE4B (Figure 3.9b). 
 
3.4 Biochemical verification of compound resistance 
I used site-directed mutagenesis PCR to introduce mutant allele coding for mutant PDE4BT407A 
protein in pET15b vector. This approach was followed by transformation of both mutant 
PDE4BT407A and WTPDE4B+ expressing vectors in E. coli competent cells for protein 
purification (Figure 3.10). E. coli transformants expressing the catalytic domain of either wild-type 
PDE4B+ or mutant PDE4BT407A T407A proteins were purified by two steps: affinity and ion-
exchange purifications. Both enzymes were successfully purified as seen in the SDS gel images 
(Figure 3.10). Purified proteins were confirmed by Western blot (data not shown). 
 
3.5 In vitro assays 
 
3.5.1 Determining initial velocity, turnover and enzyme efficiency 
After protein purification, I performed in vitro assays to characterize PDE4B+ and PDE4BT407A 
enzymes. The purpose of these experiments is to determine if the amino acid substitution is 
increasing the enzyme’s activity rather than reducing its sensitivity to BC54. One possibility is that 
the altered behavior in the presence of BC54 is due to an increase in its effectiveness in hydrolyzing 
cAMP and not necessarily, a loss of inhibition by BC54. To test this hypothesis, I carried out in 
vitro assays to determine the maximum velocity (Vmax). Due to the nature of this assay, it is 
difficult to determine Vmax directly. Therefore, I used the conditions to test the initial velocity as 
an indirect measurement of Vmax. The initial velocity (V0) of these enzymes is dependent on the 
concentration of substrate. However, in this case, the enzymes are saturated with 10µM cAMP, 
above the known Km for PDE4B, in a time-course that represents a linear reaction over time. Thus, 
Vmax is determined from the V0 with saturated substrate. From each experiment,  
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Figure 3.7. 5FOA growth assays of strains expressing wild type PDE4B2, PDE4B2Y233H, or 
PDE4B2T407A. A) Growth treatment of strains in the presence of BC54. B) Growth treatment of 
strains in the presence of rolipram. Values represent the average of OD600 ± standard error from 
three independent experiments. The values within each experiment represent an average of four 
replicate wells. Each experiment was incubated for 48h at 30⁰C. 
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Figure 3.7. 5FOA growth assays of strains expressing wild type PDE4B2, PDE4B2Y233H, or 
PDE4B2T407A  
 
A 
 
B 
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Figure 3.8. The amount of exogenous cAMP needed to activate PKA and repress the GFP reporter 
is a reflection of PDE activity. A rightward shift reflects increased PDE activity, while a leftward 
shift indicates reduced PDE activity. Values represent the average of normalized GFP to OD600 ± 
standard error from three independent experiments. The values within each experiment represent 
an average of four replicate wells. Each experiment was incubated for a 48h growth at 30⁰C. 
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Figure 3.8 The amount of exogenous cAMP needed to activate PKA and repress the GFP 
reporter is a reflection of PDE activity 
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Figure 3.9. GFP assays strains expressing wild type PDE4B2+ or PDE4B2T407A. A) Treatment of 
strains in the presence of BC54. B) Treatment of strains in the presence of rolipram. Values 
represent the average of normalized GFP to OD600 ± standard error bars from three independent 
experiments. The values within each experiment represent an average of four replicate wells.  Each 
experiment was incubated for a 48h growth at 30⁰C. 
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Figure 3.9 GFP assays strains expressing wild type PDE4B2+ or PDE4B2T407A  
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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a linear equation was obtained and used to calculate Vmax (Figure 3.11a, b). The Vmax values of 
wild type PDE4B+ (Figure 3.11a) were higher than in the PDE4BT407A enzyme in every experiment 
(Figure 3.11b). The protein concentration was determined by a BCA assay and was used to identify 
the concentration of the enzymes used in the Vmax experiment. The concentrations of PDE4B+ and 
PDE4BT407A are 0.65 µg/µL and 0.84 µg/µL, respectively. The turnover number was calculated by 
correcting the Vmax for the protein concentration. The enzyme efficiency was calculated based on 
the Vmax values previously obtained and adjusted according to the concentration of the proteins 
used for the assay (Figure 3.11). Based on these experiments, the wild type PDE4B+ is more 
efficient than the PDE4BT407A enzyme (Table 3.2). In addition, the turnover (number of molecules 
converted per time) is higher for PDE4B+ than for PDE4BT407A (Table 3.2). 
The results for Vmax, turnover, enzyme concentration and efficiency are summarized in Table 3.2. 
Overall, PDE4B+ is more efficient than PDE4BT407A, achieving a higher Vmax under the same 
conditions but using less protein, and converting more molecules into product over time. The next 
step is to perform IC50 for further characterization of enzyme activity in the presence of PDE4B 
inhibitors. 
 
3.5.2 IC50 assays  
To quantitate the sensitivity of PDE4BT407A to PDE4B inhibitors in comparison to PDE4B+, in vitro 
enzyme assays (IC50 assays) were performed with both enzymes in the presence of either BC54 or 
Rolipram. In these assays, their IC50 values were determined based on the concentration of the 
inhibitor with the ability to reduce the enzyme activity for each assayed enzyme in 50%.  
Nonlinear regression curves were used to determine IC50 values for both enzymes under each 
treatment (Figure 3.12). In the treatment with BC54, mutant PDE4BT407A was less sensitive to the 
inhibitor in comparison to PDE4B+ treatment where the IC50 value for the mutant PDE4BT407A was 
19-fold higher in comparison to inhibition of PDE4B+ by BC54 (Figure 3.12a). However, the IC50 
value for the mutant PDE4BT407A in the rolipram treatment was only about 4-fold higher in  
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Figure 3.10. Protein purification of the PDE4BT407A mutant protein. A) Affinity purification using 
talon beads. Purification steps were as followed: uninduced, induced, initial lysate, unbound, beads 
before elution, wash and elution (Lanes 1 to 7). B) and C) Ion-exchange purification using Q-
Sepharose column. Washes A and B (Lanes 8 and 9, respectively) were performed before elution. 
Elution initiated with buffer C1 (lane 10) and continued with the collection of three fractions per 
buffer used: buffers C2 (lanes 11-13), C3 (lanes 14-16) and C5 (Lanes 17-19). Samples 13 to 16 
were used for further concentration in Amicon tubes. This experiment was performed with T407A 
and it is representative for WTPDE4B purification steps. The IPTG induction of the lac promoter 
was performed as described in section 2.2.8. The SDS –PAGE gel was the method of detection 
used using Commassie blue stain. L corresponds to the Protein ladder described in chapter 2. All 
protein stocks were stored at -80ₒC. 
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Figure 3.10 Protein purification of the PDE4BT407A mutant protein 
  A                                                                                                         B 
 
 
                                  C 
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comparison to WTPDE4B (Figure 3.12b). Overall, IC50 assays demonstrated that PDE4BT407A is 
has a decreased affinity to both PDE4 inhibitors tested.  
 
3.6 Conclusion 
In this chapter, I demonstrated the development of a genetic screen to identified PDE4 alleles with 
altered behavior in the presence of BC54. This screen was used the survival phenotype associated 
with PKA activity. Furthermore, I have identified and characterized two PDE4B-resistant alleles 
to BC54 using two cell-based assays along with in vitro assays. The two mutant enzymes have 
single amino acids as followed: PDE4BY233H and PDE4BT407A. Both mutant proteins are resistant to 
BC54 as well as rolipram. In addition, our data suggest that both PDE4B mutant proteins are less 
active than the wild type PDE4B. This decrease in activity does not seem correlate with increase in 
hydrolysis of cAMP. I can conclude this genetic screen is a great tool to generate PDE mutants. In 
the future, we can generate a larger collection of PDE mutants for further characterization of their 
enzymatic activity. Another approach is to introduce these two mutations in other PDE4 isoforms 
and assess differences in enzyme activity and inhibition. I believe the generation of mutants and 
treatment in the presence of compounds will help us have a better understanding in the mechanism 
of interaction of PDEs and their regulators. 
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Figure 3.11. Vmax values based on a linear reaction with time. A) Vmax of WTPDE4B enzyme. 
B) Vmax of T407A enzyme. Values represent the Vo of two separate experiments. Linear equation 
(on the right) in every experiment was used to calculate V0 that under saturating conditions 
represent Vmax. The dilutions used for the WTPDE4B and T407A were 1:10,000 and 1:20,000 
and 40µL was assayed for each enzyme. 
  
88 
 
Figure 3.11 Vmax values based on a linear reaction with time 
A 
 
B 
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Table 3.2. Properties of  enzyme kinectics for PDE4B2 and PDE4B2T407 enzymes 
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Figure 3.12. IC50 assays. A) Inhibition of PDE4Bwt and PDE4BT407A by BC54. B) Inhibition of 
PDE4Bwt and PDE4BT407A by Rolipram. 
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Figure 3.12 IC50 assays 
 
A 
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CHAPTER FOUR 
DEVELOPMENT OF A HIGH THROUGHPUT SCREEN 
FOR PDE ACTIVATORS 
 
 4.1 Development of a chemical screen for phosphodiesterase activators 
Small molecule regulators of PDEs are important as chemical probes to study the roles of individual 
PDEs and as potential therapeutics. While there have been many efforts by both academia and 
industry to develop PDE inhibitors, relatively little work has been done to identify small molecule 
activators of PDEs. Therefore, I used a cell-based GFP assay to develop a HTS that is better-suited 
to detect small-molecule PDE activators that reduce PKA activity than a screen based on expression 
of the fbp1-ura4 reporter that has been used to detect PDE inhibitors (Figure 2.2b) (de Medeiros et 
al., 2015). As a proof of concept for this screening platform, I carried out a 10,000 compound screen 
for small molecule activators of the human PDE4D3 enzyme. The screening strain (CHP1702) 
expresses PDE4D3 enzyme that possesses an N-terminal inhibitory domain, which displays less 
PDE activity than does a strain expressing PDE4D2 (CHP1742) that lacks this domain (Figure 
1.3b). Due to lack of known PDE4 activators, we used CHP1742 as a control due to its higher 
PDE4D activity. Thus, CHP1742 produces a higher GFP signal in comparison to the screening 
strain (Figure 4.1a). Further, since the PKA level in a strain also affects its growth rate, GFP values 
have been normalized by OD600 values (Figure 4.1b). The normalized values are summarized in 
Table 4.1. 
Strains used in this screen (CHP1702 and CHP1742) were generated as previously described in 
section 3.1, but expressing the fbp1-GFP reporter (Table 2.1) (de Medeiros et al., 2015). By 
matching the level of cAMP synthesis in strains carrying various mutations affecting the fission 
yeast glucose/cAMP pathway with the activity of a target PDE, we are able to generate sensitized 
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strains that require more exogenous cAMP than strains lacking PDE expression to reduce GFP 
signal to 10 units. As seen in Figure 4.2 using strains for which exogenous cAMP is used to control 
PKA activity, a normalized GFP signal of 10 units reflects a level of PKA activity for which a 
further reduction should be detectable when treating PDE-expressing strains with small molecule 
activators of a given PDE. In order to keep the reporter off for proper assessment of compound hits 
for PDE4D3, exogenous cAMP was added to EMM medium during the growth of both 
experimental and control strains prior to initiating the GFP assay (Table 2.3). 
 
4.2 Optimization of fission yeast HTS for PDE activators 
The optimal conditions for a robust PDE activator HTS should provide a large difference in the 
fluorescence signal in cells that have been exposed to a PDE activator when compared to control 
cells exposed to the vehicle DMSO. In order to keep the well-to-well variability low, the fluorescent 
signal is normalized to the optical density (OD600) of the cultures. The assay development involved 
3 steps: (1) establishment of pre-assay growth conditions that repress the GFP reporter, which 
promotes proper assessment of activation of PDE in the presence of compound and comparison to 
fluorescence of control; (2) determination of an optimal initial cell density; (3) establishment of the 
type of readings taken at 0 and 48-h.  
The best conditions for GFP assays with either PDE4D3- or PDE4D2 –expressing strains were the 
addition of 20mM cAMP in the pre-growth of cells in EMM medium, and three washes for 
complete removal of cAMP prior to the screening. The initial cell density of 4 x 106 cells/mL allows 
cells to grow to saturation (OD ~ 1) after 48h at 30ₒ C. The GFP values are higher and OD600 values 
are lower in the control strain versus the experimental strain as an indicative of low PKA activity 
in the control strain (Figure 4.1a, b). 
Once the conditions for the HTS were established, a mock assay was performed to determine the 
Z’-factor, which is a statistical measurement of the robustness of the screen (Franz et al., 2007). In 
this screen, the Z’-factor corresponds to the difference between the positive control (genetic control 
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treated with DMSO) and the negative control (experimental strain treated with DMSO), based on 
the variation among data-points. A robust HTS produces Z’-factor values between 0.5 and 1 and is 
calculated using the following formula:  
 
 
where σ and µ represent the standard deviation and the mean, respectively, for both positive (p) 
and negative (n) controls. 
The appropriate conditions for data analyses were taken by collecting top and bottom readings of 
both GFP and OD600 values. The bottom reading provides the most appropriate data assessment 
because the fluorescing cells are concentrated on the bottom of the well. GFP values are collected 
as described in section 2.2.12. In addition, GFP and OD600 values were collected at 48h (prior to 
incubation) to identify fluorescent compounds. The GFP values at 0h and 48h (Figure 4.3a, b) and 
OD values (Figure 4.3c) can be visualized using the Vortex software.  
 
4.3 Screen with a compound library 
The HTS screen for PDE4D3 activators was performed at the ICCB-Longwood Screening Facility 
at Harvard Medical School. The Chembridge 3 library was chosen for this initial HTS for PDE4D3 
activators and has a total of 10,560 compounds. The chemical screening, comprised of several 
steps, from delivery of the cells to pinning of compounds, data collection and analyses (Figure 
4.4a). In the initial step, 30µL of cells in EMM were delivered into 384-well plates in duplicates 
and 100nL of compounds from the library plates were pinned into the wells followed by incubation 
for 48h at 30ₒ C. The compound stock solutions from Chembridge were generally at ~5mg/mL as 
the initial concentration with a final concentration of ~30µM. The controls were included in every 
screening plate in column 23 (negative controls) and column 24 (positive controls) (Figure 4.4b). 
Fluorescence and OD600 values were initially assessed with the use of theVortex software (Figure 
4.3) and followed by calculation of Z-factor and Z-scores as previously described (sections 2.2.11.1  
Z’-factor = 1 – 3(σp + σn) 
                           (µp – µn) 
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Figure 4.1. Heatmap displaying reproducibility of GPF and OD values from screening and control 
strains. A) Heatmap of fluorescence readings. B) Heatmap of OD600 readings. Screening strain 
CHP1702 was delivered in columns 1 to 12. Positive control strain CHP1742 was delivered in 
columns 13 to 24. Blue indicates low GFP (400,000 units) or OD values (below 0.5). Red indicates 
high GFP (Above 800,000 units) or OD values (~1.0). This assay was used to estimate the 
robustness of the assay (Z’-factor; see Table 4.1). Readings were taken after a 48h incubation at 
30ₒC.  
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Figure 4.1 Heatmap displaying reproducibility of GPF and OD values from screening and control 
strains. 
A 
 
B 
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Table 4.1. Normalized Fluorescence of optimized HTS 
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Figure 4.2. Cells expressing PDE4B require more exogenous cAMP than a strain lacking PDE 
activity to repress GFP reporter. In cells lacking AC activity, the amount of exogenous cAMP 
needed to reduce the GFP fluorescence is a reflection of PDE activity. In this experiment, the GFP 
fluorescence (normalized to the OD600) was compared between a strain lacking PDE activity and 
strains expressing different PDEs. These results are consistent through a range of initial cell 
densities (2x106 to 5x106cells/ml) and show that PDE4B2 activity can hydrolyze some of the 
exogenous cAMP to increase GFP expression. It also shows that for strains that have an intact AC 
enzyme, a value of ~10 units represents a level of PKA activity for which a further reduction in 
activity would likely cause a detectable elevation in the GFP signal. 
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Figure 4.2 Cells expressing PDE4B require more exogenous cAMP than a strain lacking PDE 
activity to repress GFP reporter.  
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and 4.2). Variations of raw GFP and OD values were analyzed by Vortex software (Figure 4.5). 
These variations are generally due to fluorescence, well-to-well variation, and temperature changes 
during incubation. 
For each compound, a Z-score was calculated. Z-scores represent the number of standard deviations 
above or below from the mean of the negative controls wells. Z-scores above 6 are considered 
“hits” and compounds that produce the highest Z-scores in both duplicates are selected for a Cherry-
Pick for further validation as long as they do not appear to be fluorescent or toxic. In this screen, 
the classification of Z-scores was required for a better selection of hits. The classification is listed 
in Table 4.2.  
 
4.4 Validation of primary screen Hits 
 
4.4.1 Selection of compounds for cherry-pick experiments 
At the end of the primary screening, 1,015 compounds were identified as candidate hits, however 
963 compounds could be eliminated as either fluorescent or toxic compounds that would produce 
a false positive value in this assay. The first step to reconfirm the remaining hits is to analyze the 
Z-scores, as mentioned in Table 4.2, to create a list of candidate hits for cherry pick. Typically, 
only 0.3% of the total library tested can be rescreened in the Cherry-pick assays. However, as this 
was our first effort using this new HTS for PDE activators, 52 compounds were selected for 
validation in the Cherry-pick assays (Figure 4.6). This selection was based on their Z-score values.  
The compound candidate hits were rescreened against the PDE4D3-expressing strain and against 
yeast strains expressing a combination of mammalian AC4 and PDE4D3 (CHP1807) or 
mammalian AC4 only (CHP1812). The rationale for choosing these strains is that a PDE activator 
will be a hit in strains that express the PDE4D3 enzyme, while false positives will appear to act on 
CHP1812 as well. After the screening, false positive compounds for PDE4D3 were eliminated. 
These compounds were increasing fluorescence by hitting targets other than our enzyme of interest,  
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Figure 4.3. Qualitative data overview of 10,000 compound screen. A) Average of fluorescence at 
time zero. B) Average of Fluorescence at 48h. C) Average of OD600 at 48h. Data analyses was 
performed using Vortex Software. Color coding: Cyan= Experimental sample; Dark blue= 
Negative controls; Red= Positive controls. This experiment was performed in duplicates. The Y-
axis indicates the average values of either fluorescence or OD. The X-axis indicates the plate and 
well of each compound treatment. 
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Figure 4.3 Qualitative data overview of 10,000 compound screen 
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Figure 4.4. High throughput screen for PDE4D3 activators. A) HTS steps are composed of delivery 
of the cells using a cell dispenser to pinning of compounds using a robot, followed by data 
collection using Envision which produces a heatmap as it reads each plate followed by data analysis 
by calculating Z’-factor for quality of assay and further progress of the HTS. B) Example of a 
screening plate readout. The column 23 and 24 contain negative (CHP1702 treated with DMSO) 
and positive controls (CHP1742 treated with DMSO), respectively. The colors of wells represent 
their fluorescence values, increasing from blue to red. Hit compounds were identified based on the 
higher normalized GFP of the cultures. 
  
106 
 
Figure 4.4. High throughput screen for PDE4D3 activators 
 
A 
 
 
B 
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Table 4.2. Classification of Hits according to Z-scores of duplicates 
 
 
  
108 
 
Figure 4.5. Results of the HTS. A) Scatter plot representing fluorescence values for duplicate wells 
pinned with 100nL of compounds or DMSO. B) Scatter plot representing OD values for duplicate 
wells pinned with 100nL of compounds or DMSO. Values along the X and Y axis represent the 
results from each of a pair of duplicate plates. Experimental samples treated with compounds are 
depicted in cyan circles. Negative controls treated with DMSO are depicted in dark blue circles. 
Positive controls treated with DMSO are depicted in red circles. 
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Figure 4.5. Results of the HTS 
 
A 
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PDE4D3. A total of 20 compounds were selected for counter-screen assays at Boston College 
(Table 4.3).  
 
4.4.2 Counter-screen assays 
The 20 candidate PDE4D3 activators were subjected to counter-screen assays in an effort to 
confirm their putative activity. I used GFP assays to evaluate candidate hits and eliminate false-
positive or non-selective candidates. The same strains used for the Cherry-pick assays were used 
for the GFP assays (Figure 4.7a, b, c). To simplify nomenclature, the candidate compounds were 
named A1 to A20. The rationale was to quickly eliminate compounds that were targeting proteins 
other than PDE4D3. Based on this GFP assessment, compounds A2, A4 and A14 were eliminated 
due to increase in fluorescence in treatment with strain CHP1812 that does not express PDE4D3 
(Figure 4.7c). To better visualize treatment of compounds with the three chosen strains, two 
candidates will be shown (Figure 4.8a, b). 
Both the A11 and A17 compounds promoted an increase of GFP fluorescence in the strains 
expressing PDE4D3 (Figure 4.8a, b). The strain expressing the fission yeast AC has a slight 
increase in fluorescence compared to the strain expressing mammalian AC, which reflects the 
stronger AC activity in fission yeast in comparison to the mammalian AC. Both compounds had 
no effect in the strain CHP1812, which lacks PDE activity (Figure 4.8a, b). Furthermore, neither 
compound was validated as I was unable to demonstrate a decrease in cAMP levels using cAMP 
assays (data not shown). The summary of the HTS is depicted in Table 4.4. Although, there were 
no confirmed candidate PDE4D3 activators, our yeast –based HTS successfully shows that we can 
successfully detect increased GFP, but that it may not reflect a change in PKA activity. 
The lack of validation of the potential hits points out a potential issue with the assay or may be 
difficult to detect fluorescence levels that are associated with PDE activity. Therefore, if one wants 
to find compounds that act by reducing PKA activity, it may be easier to detect AC inhibitors than 
it is to find PDE activators, as the decrease in production of cAMP and consequent of PKA activity  
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Figure 4.6. Pie-chart of candidate hit compounds. A total of 1,015 candidate hits were identified 
in the primary screen. After elimination of toxic and fluorescent compounds, 52 compounds were 
rescreened for validation. After that, 20 compounds were selected for further testing in counter-
screens. 
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Figure 4.6 Pie-chart of candidate hit compounds 
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Table 4.3 List of Chembridge compounds selected for secondary screens 
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Figure 4.7. Counter-screen of compounds A1 to A20. A) Strain CHP1702 treated with compounds. 
B) Strain CHP1807 treated with compounds. C) Strain CHP1812 treated with compounds. This 
screen was carried out with strains that express either fission yeast AC (1702) or mammalian AC 
(1807) along with PDE4D3 or expressing only mammalian AC with no PDE (1812). All strains 
were treated with all 20 candidate hits. Experiments were performed in quadruplicates. All plates 
were incubated for 48h at 30⁰C. 
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Figure 4.7 Counter-screen of compounds A1 to A20 
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Figure 4.8. Counter-screen of compounds A11 and A17. A) Counter-screen of compound A11 and 
B) Counter-screen of compound A17 with three strains. This screen was carried out with strains 
that express either fission yeast AC (1702) or mammalian AC (1807) along with PDE4D3 or 
expressing only mammalian AC with no PDE (1812).  
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Figure 4.8. Counter-screen of compounds A11 and A17 
A 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
  
119 
 
Table 4.4. Characterization of candidate PDE4D3 candidates 
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can be greater than inhibiting its regulator responsible for its destruction. In an effort to diminish 
potential problems with the assay and identify AC inhibitors, the next step is to expand HTS 
screening two strains in parallel to identify AC and GNAS1 inhibitors along with PDE activators.  
 
4.5 Conclusion  
 
There has been a remarkable effort to understand PDE structure, regulation and function. In the 
past few years, many inhibitors have been designed and placed into clinical trials. To fully 
understand PDE regulation is important to know not only what happens when enzyme activity is 
inhibited, but what happens when the enzyme activity is increased. Despite the need, there are no 
know small molecule activators of PDE4 enzymes. Therefore, I developed a HTS screen to identify 
PDE activators. Using a yeast HTS screen, I was able to detect candidate hits based on increased 
fluorescence. However, the potential hits were not validated. To exclude the possibility of technical 
issues with the assay itself or with the difficulty to screen for PDE activators, I suggest to expand 
the HTS comparing two strains along with the inclusion of AC inhibitor screening in future 
experiments. 
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CHAPTER FIVE 
HIGH THROUGHPUT SCREEN FOR PDE ACTIVATORS 
OR AC/GNAS1 INHIBITORS 
 
5.1 HTS for small molecules that reduce PKA activity using commercial libraries 
The data presented in chapter 4 demonstrate that the fbp1- GFP reporter can be used for a robust 
assay detecting small molecules that increase fluorescence. However, I have not completely 
eliminated problems with false positives. In this chapter, I have expanded the screen for compounds 
that reduce PKA activity to include target proteins involved in cAMP production and made two 
changes from the chapter 4 screen that are designed to increase the likelihood of success: the 
inclusion of a counter-screen strain and the expansion of the screen to 100,000 compounds. 
I used the 10,000 HTS as a proof of concept to develop a HTS that is better-suited to detect small-
molecules that reduce PKA activity, which would include PDE activators and AC or GNAS1 
inhibitors (Figure 5.1). This screen was HTS performed at ICCB- Longwood Screening Facility at 
Harvard Medical school. The screening process was similar to that described in Chapter 4, however 
fluorescence at T=0 was not determined since I used a counter-screen strain in parallel to the 
screening strain that should identify false positives due to fluorescence. For this HTS, I used two 
strains (CHP1823 and CHP1882) along with the positive control strain (CHP1742). These strains 
have basal GFP values that are somewhat similar and were in a level that are great for screening. 
The screening strain (CHP1823) expresses PDE4D3 enzyme that possesses an N-terminal 
inhibitory domain, as mentioned in Chapter 4. Strain CHP1882 was used as the counter-screen to 
help eliminate nonselective hits and false positives.  In addition to the expression of different PDEs, 
the screening strain expresses AC5 and the counter-screen expresses AC1 (Table 2.1). The lack of 
validation for the potential hits described in Chapter 4, raised concerns to both a technical problem  
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Figure 5.1. HTS for compounds that reduce PKA activity. HTS with two strains in parallel 
targeting five mammalian genes (PDE4D3 and AC5 or PDE7B1, AC1 and GNAS1). Small 
molecules of interest will increase the GFP signal (Figure acquired from Dr. Hoffman). 
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Figure 5.1 HTS for compounds that reduce PKA activity 
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with the assay and/or difficulty in screening PDE activators. Therefore, I decided to perform a HTS 
with two strains in parallel and screen for AC inhibitors as well. 
I screened 100,000 compounds in duplicate from commercial libraries against the PDE4D3- and 
AC5- expressing strain (CHP1823) and the PDE7B1-, AC1- and GNAS1- expressing strain 
(CHP1882). The library collections used are listed in Table 5.1. In order to consider a compound a 
hit for the screening strain, the Z-score was calculated to individual wells as described in Chapter 
2. In the 10,000 HTS, I calculated the Z-scores using mean and standard deviations as the statistic 
response to the negative controls wells. In the screen described in this chapter, I initially employed 
the same statistical analysis. However, the standard deviations were so low that it created a large 
number of candidate hits, defeating the purposes of the screen to find few but specific small 
molecules. For this reason, I decided to calculate the Z-scores using median and median absolute 
deviation (MAD) of the experimental samples, which gave a more conservative estimate of hit 
compounds. In Table 5.2, I list two examples that the change in the Z-scores analyses helped us 
eliminate false positives. Both small molecules were initially considered hits for the screening 
strain with Z-scores equal or above 12 (Table 5.2), but were eliminated once Z-scores were 
calculated taking into account variation of the experimental samples instead of the negative 
controls. Each compound was tested in duplicate wells.  
In the analyses of the GFP and OD600 values, variations were observed on different experiments, as 
demonstrated by differences of fluorescence and absorbance seen in experiments performed in 
different days. These variations usually are likely due to three main factors: GFP variation from 
well-to-well (possibly reflecting fluorescent compounds with poor solubility such that they are not 
reproducibly delivered to each well), temperature fluctuations during incubation and cell behavior 
in the presence of different compounds. However, in this screening the main factor for fluorescence 
variation was due to changes in the instrument used for data collection. It is important to note that 
these variations affected the screening, counter-screen and positive control strains equally. In 
addition, fluorescence values of the duplicates were normalized by the absorbance to decrease these  
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Table 5.1. List of commercial libraries screened at ICCB – Longwood Screening Facility* 
.  
*List is presented in screened order in HTS 
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Table 5.2 Analyses of duplicate Z-scores to eliminate false-positives* 
 
Z scores based on average and standard deviation (SD) from DMSO treated wells. Z scores based 
on median and MAD of experimental samples. All values were analyzed from duplicate wells. 
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Figure 5.2. Scatter plot of normalized fluorescence. The scatter plot represents the fluorescence 
intensity in duplicates for screening strain CHP1823 (left) and counter-screen strain CHP1882 
(right). Cyan circles represent experimental samples treated with small molecules. Dark blue circles 
represent negative controls. Red circles represent positive controls. Red arrow indicates a 
fluorescent and nonselective hit. 
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Figure 5.2 Scatter plot of normalized fluorescence 
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variations (Figure 5.2).  
From the libraries used, a total of 2,176 compounds were annotated as hits, but only 727 of those 
hits were annotated for our screening strain. Most of the potential compound hits for the screening 
strain were eliminated due to various reasons, such as: fluorescence, toxicity, counter-screen hits, 
high LogP (a measurement for compound solubility) or a combination of at least two of these 
characteristics (Figure 5.3). The analyses for elimination of five out of eight potential hits are listed 
in Table 5.3. 
 
5.2 Evaluation of the Primary screen 
The first analysis of a pin appointment is to determine the quality of the library plate against the 
screening and counter-screen strains based on Z’-factor described in Chapters 2 and 4. The 
qualitative analyses are done with the Vortex software provided by the ICCB screening facility. 
Scatter plots can depict both the average fluorescence and average absorbance by plate-well for 
each strain (Figure 5.4). In this type of analysis, the screener can assess which compounds are 
specific or nonselective hits that appear in the scatter plots of both strains, respectively (Figure 5.4 
a and b, red arrow). In addition, compounds can be eliminated on the basis of low OD values, which 
indicate toxicity (Figure 5.4 c and d). It can also indicate technical problems such as edge effects, 
which can cause the samples to form a smile shape on the grid (Figure 5.4 c and d, black arrows). 
Furthermore, it allows one to correlate the normalized fluorescence of the replicates for the 
respective strains, to identify wells with spikes in counts that may indicate auto-fluorescent 
compounds or to identify non-selective compounds (Figures 5.2 and 5.4a and b, red arrows), and 
to visualize potential hits for each strain as highlighted with asterisks in Figures 5.2 and 5.4.  
The edge effects or well bias as seen in Figure 5.4 can also be analyzed by the scatter by size of 
signal per well (data not shown). No edge effect was observed in the majority of the pin 
appointments. In addition, variations caused by edge effect or temperature fluctuations can been 
seen in a 3D histogram that analyzes the average of the normalized fluorescence in each well for 
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Figure 5.3. Potential candidate hits in the Primary screen. The top pie chart represents the total 
number of hits and their distribution for the Primary HTS. The bottom pie chart represents the 
number of hits for the screening strain and elimination of hits due to fluorescence, toxicity, potential 
solubility issues (high Log P), or a combination thereof. The total of small molecules selected for 
cherry pick experiments is depicted in the bottom pie chart in light green. 
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Figure 5.3 Potential candidate hits in the Primary screen 
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Table 5.3. Elimination of potential candidate hits* 
 
*Type represent the compounds that were cherry-picked (C). Hit are classified as strong (S), 
moderate (M) or weak (W)FA. OD are in conditional formatting from red (low OD) to green (high 
OD). Z-scores are color coded in pink from stronger (>15) to weak (<10) hits.  Elimination due to 
Toxicity (T), to Fluorescence (F), to LogP (L) or counter-screen (X) are indicated.  
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Figure 5.4. Qualitative Data Overview. Average of Fluorescence for screening strain (CHP1823) 
after 48h (A). Average of Fluorescence of screening strain (CHP1882) after 48h (B). Average of 
OD600 for screening strain (C) and counter-screen strain (D) after 48h. Data analysis was performed 
using Vortex Software. Color coding: Cyan= Experimental sample; Dark blue= Negative controls; 
Red= Positive controls. This experiment was performed in duplicate. Red arrows represent 
nonselective compounds (likely due to autofluorescence given the extremely high value). Black 
arrows represent the edge effect. Asterisks represent different small molecules that increase GFP 
values specifically for one strain. 
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Figure 5.4 Qualitative Data Overview 
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both replicates (Figure 5.5). Moreover, this type of map can indicate potential hits based on high 
fluorescence values. For instance, some wells have fluorescence above 800,000 GFP units/OD, 
which correspond to the positive control values (Figure 5.5). However, it is still possible that the 
positive hits will be eliminated due to reasons depicted on Figure 5.4. 
In conclusion, a combination of qualitative (the data analyzed with the software) and quantitative 
(data analyzed by median and MAD) analyses were used to identify potential candidate hits using 
normalized Z-score values and GFP values for both duplicates of the screening strain. The counter-
screen allowed us to eliminate fluorescent and nonselective hits (Figure 5.4, red arrows). At the 
end of the primary screen, I detected 113 potential candidate hits for the screening strain (Figure 
5.4). The following sections described efforts to validate these potential candidates that were hits 
for the screening strain CHP1823 in more detail.  
 
5.2.1 Selection of the Primary screen hits 
As already mentioned, 727 compounds produced Z-scores of >6 in both replicates for the screening 
strain. From 727 compounds only 113 of those were annotated as hits for cherry pick assays (11 
strong hits (Z- scores > 15), 22 moderate hits (Z-scores < 15, but >10) and 80 weak hits (< 10 and 
> 6) (Figure 5.6). In addition, I compared the sum of the duplicate Z-scores for each strain defining 
a Z-score differential as the sum for the screening strain minus the sum for the counter-screen strain. 
We can observe that positive Z-score differentials above 12 indicate hits for the screening strain 
and negative Z-scores below 12 indicate hits for the counter-screen strain (see Table 5.4 for an 
example of how this analysis was carried out). Therefore, Z-differentials help the process for 
selection of hits to validate in the Cherry picks experiments.  
 
5.2.2 Optimization for Cherry-pick experiments 
I was concerned with the possibility that a hit compound could affect transcription of the target  
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Figure 5.5. 3D Histogram of normalized fluorescence. Variation of normalized fluorescence values 
can be observed in 3D. Dark blue columns indicate fluorescence above 600,000 GFP units/OD600. 
The histogram is a representative of the average normalized fluorescence of both duplicates from 
a single library plate. Col Y represents Columns 1 to 24 and Row X represents rows A to P in a 
384-well plate. 
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Figure 5.5 3D Histogram of normalized fluorescence 
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Figure 5.6. Selection of small molecules for cherry pick experiments. The pie chart on the left 
represents the total of compounds with Z-scores were above 6 in both duplicate in the screening 
strain. In addition, it depicts the number of the compounds eliminated. The part chart of the right 
represents the total compounds selected and classified as strong (>15), moderate (<15 and >10) and 
weak (<10 and >6). 
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Figure 5.6 Selection of small molecules for cherry pick experiments 
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Table 5.4. Examples for the evaluation of potential hits based on Z-scores 
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gene instead of the enzyme activity. Therefore, I wanted to test strains that expressed the same 
enzyme from two different promoters. Depending on the strength of the promoter such as adh1, the 
AC or PDE expression can be stronger (Hoffman lab, unpublished). Therefore, the first step for 
optimization is to analyze if expression of PDE or AC was affected due to the compound targeting 
the promoter and not the protein of interest. These experiments were carried out at Boston College. 
For this first part, I wanted to determine if the compounds inhibit the adh1 promoter. In this case, 
if there is a regulation of transcription, I will observe a minimal increase of 10% in GFP values in 
strains CHP1805, CHP1823 and CHP1962 in comparison to DMSO treatment. In addition, I 
wanted to select strains that can distinguish among the target proteins. I tested six different strains 
that expressed different combinations of AC with PDE to verify if selectivity can be determined 
(CHP1805, CHP1823, CHP1882, CHP1911, CHP1962 and CHP1966; Table 5.5) in the presence 
of compounds Therefore, if compounds are targeting PDE4D3, the GFP values will increase in 
strains CHP1805, CHP1823 and CHP1911. If compounds are targeting AC5, GFP values will 
increase in strains CHP1823 and CHP1966. The rationale of this experiment is summarized in 
Table 5.5. 
For these experiments, six compounds were purchased in advance for further testing at Boston 
College. I treated these strains with compounds we purchased based on their high GFP value in the 
primary screen (BC23 -4, -5, -6, -7, -8) along with a designed compound BC23-1 and Progesterone 
(a hit for the counter-screen) and DMSO as a control. Qualitative results for the pilot experiment 
are summarized in Table 5.6. Based on our data, compounds are not inhibiting the adh1 promoter. 
In addition, strains CHP1911, CHP1962 and CHP1966 were eliminated due to lack of growth in 
the presence of compounds. Moreover, results suggest that BC23-4, -5, -7 and Progesterone are 
nonselective AC inhibitors (Table 5.6). 
After the in-house pilot test, I tested three strains with the same compounds depicted in Table 5.6 
using the cherry pick compounds and instrumentation from ICCB Screening facility. In the pilot 
test for the cherry pick, I chose two strains (CHP1805 and CHP1822) along with the screening  
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Table 5.5. Pilot experiment to evaluate candidate compounds prior to cherry-pick experiments 
 
  
(+) represents increase in GFP values in comparison to control; (-) represents decrease in GFP 
values in comparison to control. 
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Table 5.6. Results for pilot experiment 
 
(+) represents increase in GFP values in comparison to control; (-) represents decrease in GFP 
values in comparison to control; P represents Progesterone. 
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strain (CHP1823) (Table 5.7). All of the strains have the AC expression driven by the adh1 
promoter. The complete genotype of the strains used for optimization procedures are listed in Table  
2.3. Based on our data, it seems that BC23-1/-6/-8 do not target any enzyme of interest and it 
suggests that BC23-4, -5, and -7 are non-selective AC inhibitors (Table 5.7). Unlike our in-house 
pilot experiment, BC23-1 and Progesterone failed to increase the GFP values in strains CHP1805  
and CHP1823 (Table 5.7). These discrepancies will be discussed in Chapter 6. Overall, this 
experiment seems promising since it can distinctly identify compounds that are either targeting the 
screening strain expressing the proteins of interest or targeting in a non-selective manner. After 
these preliminary results, I moved forward with the cherry pick assays. To further eliminate non-
selective compounds, I included the strains CHP2028 (PDE7B1- and AC6- expressing strain) in 
the cherry pick experiments. 
 
5.2.3 Validation of potential candidate hits using Cherry-pick experiments 
I performed a GFP assays testing 2.5-fold dilutions of compounds from 0.625 µM to 5 µM. In this 
way, I could test for potency of the compounds. I also used three strains along with the screening 
strain to test for selectivity. A total of 70 out of 113 compounds yielded at least a 10% increase in 
the normalized fluorescence values for the highest compound at the concentration tested (5µM) for 
the screening strain. 
Although 70 compounds were validated, only 17 compounds were used for further confirmation in 
the secondary screenings. A total of 49 potential hits were eliminated due to non-selectivity or 
likely fluorescence of the compounds. These compounds were selected on the basis of potency and 
to a certain level of selectivity. The data for each compound hit are summarized in Table 5.8. Most 
of the compounds were non-selective. However, the compounds that were selected for secondary 
assays promoted a greater increase in GFP values higher in the screening strain and/or in both AC5-
expressing strains than in the other two strains. Compounds were eliminated if they produced an 
increase in fluorescence signal in only one of the duplicates or if there was too much variation  
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Table 5.7. Pilot test results of candidate hit compounds at ICCB  
 
(+) represents increase in GFP values in comparison to DMSO control; (-) represents decrease in 
GFP values in comparison to control; P represents Progesterone. 
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Table 5.8. Compounds examined in cherry pick experiments with comments on cherry pick 
results 
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between both duplicates in comparison to DMSO control. It is worth to note that no toxicity was  
detected in the cherry pick experiments (data not shown). Overall, testing against three additional 
strains helped eliminate 63 compounds out of 113. In addition to the 17 compounds, 8 compounds 
(7 hits from the Primary screen and I designed compound BC23-1) were included in the counter-
screen experiments. A summary of the 25 candidate hits selected for the counter-screens is listed 
in Table 5.9. 
 
5.3 Secondary assays to confirm potential candidates as final hits 
To characterize the 17 lead compounds along with 8 compounds purchased by us due to their 
performance in the primary screen, I used cAMP and GFP assays, as described in Chapter 2. The 
data were not reproducible in either assay (data not shown). For example, the cAMP levels appeared 
to drop upon compound treatment in some assays, but not upon repeating the experiment. 
Therefore, no compounds could be validated using the screening strain with these assays since they 
seemed to target the different proteins expressed in screening and counter-screen strains giving 
similar GFP values. Conversely, non-target proteins expressing strain (CHP2053), genotype listed 
on Table 2.3, confirmed that most of these compounds have no effect in S. pombe strain expressing 
non-target proteins. The GFP values for strain CHP2053 treated with 25 compounds are depicted 
in Figure 5.7. The majority of the compounds had GFP values below 11 units/OD at the highest 
concentration tested. However, compounds BC23-6,-8,-10, -12, -13 and -19 had values above 13 
units/OD at the highest concentration (Figure 5.7). Although, use of counter-screen would reduce 
technical issues, I believe that these elevations are artifacts, which could explain why they appear 
as hits in the primary screen. Moreover, the treatment of CHP2053 strain with compounds BC23-
5 and -19 yielded OD values below 0.35 (data not shown), which suggests a possible toxicity effect 
that was not previously identified. Conversely, the treatment of CHP2053 strain with compounds 
BC23-6, -8 and -13 yielded high OD values, but it is possible these compounds are fluorescent. In 
summary, these experiments indicate that these compounds are having an effect against strains with 
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candidate target proteins, as our previous analyses demonstrated. Moreover, our analyses are 
supported by experiments where the compounds fail to increase fluorescence in a strain not 
expressing target proteins. However, the GFP results clearly demonstrate that the assay cannot 
validate any of candidate hits against the screening strain and assessment of potency and selectivity 
could not be made either. 
There are multiple reasons that artifacts as toxicity have not been previously detected. One caveat, 
it is the different methods used to deliver the compounds as followed: the pin transfer was used in 
the primary screen; the transfer from cassette to wells by vibration was used in the cherry picks; 
and transfer was used multichannel pipettes for the secondary assays. Another caveat that may have 
affected is the compound source. The compounds used at ICCB have been thawed many times and 
after many rounds of thawing, it is possible that I was using derivatives of the original compound 
tested. In the cherry pick, compounds are from the libraries at ICCB, but they are prepared 
exclusively from stocks. For in-house testing, the compounds were directly purchased from the 
companies. Therefore, I believe I am testing the potential hit and assessing its chemical activity 
fully. 
Due to inconsistent data for the screening strain in both GFP and cAMP assays, I decided to perform 
KCl assays as the secondary assay. In this assay, I can assess PKA activity independent from the 
use of fbp1-GFP construct expressed in the screening strain (Stiefel et al., 2004). The goal of this 
assay is to test whether a compound can confer KCl-sensitivity upon a strain that is KCl resistant 
due to high PKA activity. These assays were performed in both solid and liquid media. 
 
5.3.1 Secondary screens for assessment of PKA activity in liquid medium  
The purpose of this assay is to validate compounds that reduce PKA but independent from the 
PKA-repressible reporter carried in our strains. In salt stress conditions, strains expressing high 
PKA activity will present a KCl - resistance growth. Conversely, strains expressing low PKA 
activity will present a KCl - sensitivity growth. Therefore, I need to validate compounds against  
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Table 5.9. Small molecules selected for secondary assays 
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Bolded compounds were either not screened (BC23-1) or were hits for the Primary screen only or 
was not validated in the cherry-pick assays (BC23-19). 
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Figure 5.7. GFP assay to validate candidate hits. CHP2053 strain was treated with 25 compounds 
four series of 2.5-fold a serial dilution where the first concentration was 20 µM for each compound. 
This is a representative of a single experiment. Experiment was performed in quadruplicate. Plate 
was incubated for 48h at 30⁰C. Error bars represent standard errors. 
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Figure 5.7 GFP assay to validate candidate hits 
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strains that have high PKA activity and, consequently, have a KCl-resistance phenotype. In order 
the identify the most suitable strain for the KCl assays in liquid medium, I tested the following 
strains: the screening strain (CHP1823), the counter-screen (CHP1882), the PDE4B2 expressing 
strain (CHP1641) and the PDE4D2-, AC5- and GNAS1- expressing strain (CHP1852). These 
strains were treated at different concentrations of KCl. 
The screening and the counter-screen strains behaved similarly to strain that expresses PDE4B2 
only under KCl stress (Figure 5.8). The PDE4D2-, AC5- and GNAS1- expressing strain (CHP1852) 
presents the most distinct KCl-resistance growth phenotype. In this strain, more than 1.25M KCl is 
needed to confer KCl – sensitivity growth (Figure 5.8). However, due to variability with control 
values, I could not assess the effect of the compounds in the KCl assay in liquid media (data not 
shown). 
 
5.3.2 Secondary screens for assessment of PKA activity in solid medium 
In this assay, I chose strains that display a growth resistance phenotype in the presence of KCl in 
solid medium. Thus, if a compound has an effect, it will reduce PKA activity, which in turn will 
confer KCl sensitivity and a halo of inhibition will form. Twelve strains were used for this assay 
(Table 5.10). These strains express either the S. pombe AC (Git2), no AC with PDE4D3, or one of 
the ten mammalian AC, respectively. In these experiments, compounds BC23-18 and -21 have an 
effect in strains expressing group I (AC1 and AC8), group II (AC2 and 4) , group III (AC1 and 
AC8) and group IV (AC9). BC23-5 inhibits groups I(AC8), group III (AC5 and AC6) and group 
IV (AC9) (top panel). Further, BC23-22 seems to strongly inhibit all ACs from group I along with 
a moderate inhibition of AC9 and weak inhibition of AC5 and AC6. BC23-7 clearly shows no 
effect in solid medium, while compound BC23-19 is toxic as it inhibits growth of all strains (Figure 
5.9, top panel). Most of the other compounds behaved like BC23-7 and produced no halos. 
However, these compounds deserve further testing as the sensitivity of the assay varies somewhat 
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depending on the density of the cells plated so that it is possible that a halo would be observed on 
plates receiving fewer cells. 
 
5.4 Conclusion 
I developed and optimized a high-throughput screen for PDE activators and AC/GNAS1 inhibitors. 
In this HTS, I used a screening strain expressing PDE4D3 (long form of PDE4D that possesses an 
N-terminal inhibitory domain) and AC5 enzymes. The conditions for this assay produced Z-factors 
above 6 with MAD values around 4%. A total of 100,000 compounds from commercial libraries 
were screened and 727 hits were identified. Cherry pick assays with the candidate hits from primary 
screened were performed and 70 compounds were confirmed. However, 49 were eliminated due to 
non-selectivity. Based on our assessment of the potency and selectivity of the cherry-picked 
candidates, 17 candidate hits along with 8 additional compounds were purchased for further 
analyses. Preliminary data suggest that compound BC23-19 is toxic, inhibiting growth on 
YES+KCl for all strains tested. Most compounds were like BC23-7 that they make any halos in 
solid medium (Figure 5.9). In addition, BC23-18 and BC23-21 inhibit the same ACs in a similar 
manner. BC23-22 appears to inhibit group 1 ACs strongly followed by moderate and weak 
inhibitions of groups 4 and 3, respectively. Thus, it appears that I have identified broad specificity 
AC inhibitors, but not ones that only act on AC5. Further investigations are underway. In the future, 
enzymatic assays will need to be performed to determine enzyme affinity and potency of 
compounds. 
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Figure 5.8. Optimization of KCl assays. Assay was performed with various KCl concentrations 
against four yeast strains. This is a representative of a single experiment. The experiment was 
performed in quadruplicates. Plate was incubated for 48h at 30⁰C. Error bars indicate standard 
errors. 
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Figure 5.8 Optimization of KCl assays 
 
  
163 
 
Table 5.10. List of strains used for KCl assays in solid medium 
 
 
N-terminal inhibitory domain) and AC5 enzymes. The conditions for this assay produced Z-factors 
above 6 with MAD values around 4%. A total of 100,000 compounds from commercial libraries 
were screened and 727 hits were identified. Cherry pick assays with the candidate hits from primary  
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Figure 5.9. KCl assay in solid medium. Twelve strains were treated with six compounds. AC 
inhibition is characterized by formation of zone of inhibition in KCl solid medium. Strains were 
streaked in a clockwise direction following the strain order listed in the Table 5.10 
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Figure 5.9 KCl assays in solid medium 
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CHAPTER SIX 
 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
 
Small molecules can be used as research tools to understand the biological roles of specific target 
proteins. They can also be developed into drugs via medicinal chemistry. Our lab is interested in 
studying the modulation of key components of the cAMP pathway and have previously conducted 
screens for chemical inhibitors of cyclic nucleotide phosphodiesterases (PDEs). In this thesis, I 
wanted to address two distinct goals, as follows: 1) To have a better understanding of a promising 
PDE4/7 inhibitor, and 2) to try to develop a screen that would identify novel tool compounds that, 
rather than elevating cAMP signaling as would be the effect of a PDE inhibitor, would reduce 
cAMP signaling.  
Currently, there are several ongoing clinical trials of PDE inhibitors related to many pathologies 
from immune to central nervous system diseases (Maurice et al., 2014). Conversely, there are few 
ongoing trials in targeting ACs for disease related purposes, such as the AC6 gene transfer clinical 
trial (Hammond, 2015). It is possible that the difficulty in assessing the effectiveness of AC 
inhibitors in vivo has created barriers for the discovery and further testing of specific compounds.  
Although there has been a remarkable effort from both academia and industry to identify and 
characterize PDE inhibitors, there are no known PDE4 activators to date. The lack of PDE 
activators and assessment of AC inhibitors in cells have limited our understanding of their function 
and their potential as therapeutic targets. The aim of this study was to develop research tools that 
allow us to better investigate the roles that PDEs and ACs play in various biological processes. In 
this section, I will summarize and discuss the findings from my research. 
 
6.1 Development of a genetic screen to identify BC54-resistant PDE alleles 
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BC54 is a dual specificity PDE4/PDE7 compound discovered by our lab using a fission yeast HTS 
system. Both enzymes (PDE4 and PDE7) are involved in inflammatory response (Keravis and 
Lugnier, 2012). BC54 outperformed rolipram in mammalian cultures by reducing TNFα and IL-2 
with a 3-fold difference (Hoffman lab, unpublished). Thus, supporting BC54 anti-inflammatory 
role. 
I have developed a genetic screen to generate and characterize mammalian PDE4 and PDE7 mutant 
alleles that are resistant to BC54 (dual specificity PDE4/7 inhibitor). The purpose of this screen 
was to identify single amino acid changes in PDE4 and PDE7 that confer resistance to BC54. 
Mutant alleles were identified by growth in SC-Ura medium within the zone of inhibition of BC54 
as the retention of PDE activity leads to an increase in expression of the PKA-repressed fbp1-ura4 
reporter.  
Both stationary phase survival and growth on SC-Ura medium are phenotypes that can reflect the 
presence of PDE activity. A rapid loss of viability in stationary phase is associated with deletions 
in the cgs1 (PKA regulatory subunit) and cgs2/pde1 (PDE) genes that lead to hyperactive PKA 
(Mochizuki and Yamamoto, 1992; DeVoti et al., 1991). In order to carry out a genetic screen for 
mutant PDEs, I had to choose the appropriate strain to assess the phenotype. The ideal host strain 
is the one that produces high intracellular cAMP levels that lead to high PKA activity, such that 
expression of a functional PDE could lower PKA activity to alter its growth behavior. In addition, 
the strain can be differentiated when expressing either wild-type or mutant PDEs by the failure (the 
wild type phenotype) or ability (the mutant phenotype) to enter stationary phase in the presence of 
compound. To determine the conditions, I tested six strains that produce different levels of cAMP. 
Strain CHP1346 has a disrupted cgs2 PDE gene that can be replaced by a plasmid expressing 
PDE4B or PDE7B. In addition, CHP1346 was the only strain tested that I could differentiate failure 
to enter stationary when expressing either a wild-type or compound- resistant mutant l for both 
PDE4 and PDE7. In the most diluted samples, a PDE4B-expressing transformant displayed a 10-
fold decrease in survival, which reflects an increase in PKA activity (Figure 3.3). As described in 
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the following section, these results allowed me to enrich for rare transformants that express 
compound-resistant PDE alleles so that I would be better able to detect them when screening for 
colony formation on a plate. 
 
6.1.1 Enrichment is important to screen compound resistant transformants 
It was a reasonable assumption that the compound-resistant alleles I was screening for would be 
rare within the population of PCR-generated alleles. Therefore, an enrichment step in the procedure 
was used to increase the percent of cells among the transformants that carry alleles of interest. Pilot 
experiments demonstrated that loss of survival of cells expressing PDEs occurred rapidly (Figures 
3.3 and 3.4), which it made more difficult to assess growth of PDE transformants in the halo of 
inhibition in the SC-ura medium depicted in Figure 3.4. After enrichment, I identified two mutant 
PDE4B alleles that have an altered behavior in the presence of BC54: PDE4Y233H and PDE4T407A.  
After different attempts to identify compound-resistant PDE alleles, I can confirm that the 
enrichment was an important step to identify the mutants of interests. The enrichment killed off 
cells that failed to express an active PDE, which would include ones that fail to express PDE activity 
under any condition or ones that express a PDE that is sensitive to a PDE inhibitor that is added to 
the growth medium. Even after enrichment, relatively few of the transformants formed colonies on 
SC-ura with the BC54 zone of inhibition, suggesting that the percent of cells carrying plasmids of 
interest must have been very low after the original gap repair transformation. 
 
6.1.2 Screening for compound-resistant alleles identifies important residues in target PDEs 
PKA activity is associated with several phenotypes. Initially, I screened for mutants with an altered 
behavior in the presence of inhibitors assessing the mating phenotype (Appendix A). Although, the 
altered phenotype was detected, the compound did not necessarily affect all the cells within a 
colony. Thus, the sensitivity of the assay was relatively low. In contrast, the SC-ura phenotype 
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starts with individual cells on a plate. Therefore, if a compound fails to inhibit growth, the 
difference in colony size is noticeable.  
The SC-ura growth phenotype was the best choice for the screen, but it required the enrichment 
step looking at survival in the presence of BC54 compound. The identification of mutant PDE 
alleles based on growth in SC-ura was the best approach in comparison to the mating phenotype, 
since growth within the zone of inhibition demonstrates that the transformant colony expresses a 
PDE enzyme with reduced sensitivity to BC54. Thus, this phenotype is not only associated with 
PKA activity, but with PDE activity. In the past, colony formation in SC-ura was used to isolate git 
mutants that had fbp1 constitutive expression and low PKA activity (Hoffman and Winston, 1990). 
Therefore, it increased the chances of successful identification and characterization of mutants. 
After optimization and development of the screen, I identified two transformants expressing mutant 
alleles of PDE4B as previously mentioned. The plasmids expressing these mutant alleles were 
isolated and integrated as a single copy plasmid into the chromosome, which can be used for further 
characterization of PDE being expressed by a single plasmid to confirm the initial altered 
phenotype. I confirmed both mutant alleles of PDE4B conferred altered behavior in the presence 
of BC54 in cell-based assays.  
In a previous work from our lab, mutant alleles were stably incorporated into a genome by 
disruption of git2 locus with ura4+ marker for selection (Ivey and Hoffman, 2004). This approach 
was employed to generate mutants that helped identify the binding site of Git2 that promotes 
activation of Gpa2 using a two-hybrid screen (Gα – subunit) (Ivey and Hoffman, 2004). In this 
study, I used a different approach, which was to integrate the entire plasmid. While this method 
could have been problematic as it creates a direct repeat flanking the gene of interest, such that a 
second recombination event might remove the gene from the genome, I did not obtain any results 
that suggested this method created unstable strains. 
In the screen described in Chapter 3, I used PCR and gap repair to generate and clone mutant PDE 
alleles in S. pombe (Kostrub et al., 1998). Critical to the success of this procedure was the 
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optimization of the mutagenic PCR such that the mutant proteins I detected only possessed a single 
amino acid change. In the previous genetic screen (Appendix A), the mutant alleles identified 
carried more than one missense mutation, which made it difficult to re-confirm the initial altered 
mutant for mating phenotype in the presence of PDE inhibitor. Therefore, I optimized the 
mutagenic PCR by decreasing the number of cycles of amplification and using only buffers B, C, 
J and L from the Failsafe PCR kit (Chapter 2) that were previously shown to promote a low level 
of transition and transversion mutations (Hoffman lab, unpublished). This reduced the amount of 
mutagenesis, which allowed me to identify mutant alleles carrying single point mutations in the 
screen carried out in Chapter 3.  
Although there are other options to screen for mutant alleles such as changes in the mating 
phenotype (Appendix A), I believe the combination of enriching for mutant alleles of interest via 
stationary phase survival and screening for compound resistance by colony formation on SC-Ura 
has been the best approach to follow. The enrichment for cell survival allowed rare transformants 
of interest to increase their relative numbers within the cells to be screened. Growth on SC-Ura in 
the presence of compound is an effective phenotype to identify transformant colonies carrying 
mutations that allow the PDE to remain active.  
 
6.1.3 The value of knowing the mutants that display BC54-resistance 
Over the years, crystal structure studies have helped clarify the amino acid interactions with each 
other in the PDE catalytic site (Xu et al., 2000; Houslay and Adams, 2003). According to crystal 
structure studies of PDE4B2, the two residues altered in our mutant alleles (PDE4BY233H and 
PDE4BT407A) have been proposed to play roles in substrate binding and/or rolipram binding (Xu et 
al., 2000; Houslay and Adams, 2003). Moreover, the early structural models suggest that 
interactions of other amino acids with Tyr233 are important for stabilization of the hydrogen bond 
network. Meanwhile, Thr407 contacts the nucleotide base directly, which could be associated with 
substrate specificity for cAMP along with Thr403 playing a role in orienting Glu443 residue (Xu 
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et al., 2000, Houslay and Adams, 2003). To confirm and better understand these mutant forms of 
PDE4B, I have characterized their activity using both cell-based and in vitro approaches.  
Cell-based assays developed in our lab have been very useful to better understand the sensitivity of 
PDE proteins to specific inhibitors (Demirbas et al., 2013; Ceyhan et al., 2012; Ivey et al., 2008). 
In the present study, I used two cell-based assays that assess PDE activity, as the inhibition of PDE 
activity would either increase growth in 5FOA medium or decrease the fluorescent signal. In both 
assays, PDE4B –expressing mutant strains were resistant or partially resistant to both BC54 and 
rolipram. Although PDE4BY233H –expressing strain displayed resistance to both inhibitors, it was 
observed this mutant strain expressed a weak PDE. In the screen that identified the mutant alleles, 
transformants expressed PDE4B from a multi-copy autonomously-replicating plasmid. However, 
once integrated, only a single-copy plasmid expressed PDE4BY233H, which revealed its weak 
activity that made it unsuitable for biochemical characterization. The screen using autonomous 
multicopy plasmids is probably the reason this weak PDE was initially detectable.  
Since the T407A mutation confers reduced sensitivity both rolipram and BC54, one way to screen 
for possible allosteric inhibitors of PDE4B would be to use a strain expressing the PDE4BT407A It 
should display resistance to compounds that act through the cAMP-binding site as do rolipram and 
BC54, but remain sensitive to compounds that act through other sites. Once these compounds have 
been identified, one could then carry out a screen for alleles of PDE4B that are resistant to these 
compounds as a way of identifying the allosteric site or sites.  
The findings from the cell-based assays suggested that PDE4BT407A is potentially involved in direct 
binding of inhibitors, such that the mutant protein has a lower affinity for BC54. However, it was 
possible that this mutant is resistant due to an increase in affinity for cAMP. For this reason, I 
performed in vitro assays to examine the enzyme kinetics and determine IC50 values for both BC54 
and rolipram.  
To assess enzyme activity, I optimized the conditions to test for Vmax, enzyme efficiency and 
turnover number. Before going over the results, it is important to remember that PDE4BY233H had 
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such a weak activity that none of in vitro assays with PDE4BY233H were reproducible. Interestingly, 
this tyrosine residue is known to stabilize the interactions in the hydrogen-bonding network 
responsible for cAMP hydrolysis (Houslay and Adams, 2003; Xu et al., 2000). In in vitro assays, 
the PDE4BT407A mutant enzyme was less active than the PDE4Bwt enzyme, which is in contrast to 
results from the GFP assay suggesting that PDE4BT407A mutant strain was slightly more active than 
wild-type PDE4B (Figure 3.8). There are three possible explanations for this discrepancy between 
cell-based and in vitro assays, as followed: (1): the mutant enzyme may be more stable inside the 
cell than it is in the in vitro conditions; (2) the mutant enzyme may perform better in the cell 
cytoplasm versus in the in vitro environment; (3) I assess the full-length size of the mutant enzyme 
in the cell-based assay and only assessed the catalytic domain in the in vitro assays and it is possible 
that the full-length mutant enzyme may perform differently under in vitro conditions in comparison 
with its short form.  
As I previously mentioned, PDE4BT407A was less active than the Wild type PDE4B under in vitro 
conditions. The Vmax for PDE4BT407A was two-fold lower than that of the wild-type PDE4B under 
saturated conditions. This decrease in Vmax also reflected the decrease in enzyme efficiency of the 
mutant protein. The mutant enzyme’s ability to convert cAMP molecules into 5’AMP per minute 
also decreased in comparison to the wild type PDE4B enzyme. These results suggest that the altered 
behavior in the presence of compounds is not be due to an increase in affinity for cAMP since the 
efficiency and Vmax of the mutant enzyme is less than that of the wild type enzyme.  
Thr407 residue has previously been implicated in rolipram binding (Houslay and Adams, 2003). 
To verify that PDE4BT407A mutant protein is altered in its sensitivity to these inhibitors, I performed 
in vitro enzyme assays to determine the IC50 values for BC54 and rolipram. Consistent with the 
cell-based assays, I observed an almost 20-fold reduction in inhibition by BC54 against the mutant 
protein in comparison to the wild-type protein. In addition, there was an almost four-fold reduction 
in the IC50 for rolipram against PDE4BT407A in comparison to the wild-type PDE4B. This less 
dramatic decrease in inhibition by rolipram may be misleading and due to the use of just the 
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catalytic domain in this assay. As described earlier, monomeric forms of PDE4s display a low 
affinity for rolipram representing a conformation known as LARBS (Houslay and Adams., 2003). 
Thus the IC50 for rolipram against the catalytic domain of the wild type enzyme may be artificially 
high, which would lessen the observed effect of the mutation in this assay (Figure 3.12). One may 
see a greater effect of the mutation in assays that use the full-length enzyme with and without the 
altered residue.  
In future studies it will be interesting to introduce both Y233H and T407 mutations in PDE7 
enzymes and verify if there is a loss of sensitivity by BC54 in in vitro assays and resistant phenotype 
in cell-based assays. Tyr233 is a conserved residue in PDE4B2 (NP_001032416.1), PDE7A 
(NP_001229247.1) and PDE7B (NP_061818.1). The conservation is supported by PDE4B2 crystal 
structure studies that suggest Tyr233 role in stabilization the hydrogen bond network, which is 
important for its hydrolytic activity (Xu et al., 2000). The loss of activity seen in PDE4B T233H our 
cell-based assay supports Tyr233 role in hydrolytic activity. Thr407, on the other hand, is somewhat 
conserved. In PDE7 enzymes, there is a serine in place of the threonine. However, since both amino 
acids belong to the same biochemical group (nonpolar). By substituting the Ser for an Ala, PDE7 
enzymes we may understand if this change in residues dramatic affect the mode of inhibition of 
BC54 and, perhaps help elucidate differences in BC54 inhibition between PDE4 and PDE7 
enzymes. 
Overall, these findings suggest that these mutations are directly involved in inhibitor affinity to 
PDE4B as our results suggest that the altered response of the mutant PDEs to BC54 is not associated 
with an increase in affinity for cAMP. In addition, studies of compounds related to BC54, described 
below, have identified some pharmacophores within BC54 that appear to be important for its 
activity. Taken together, this information can help to develop a model of how BC54 binds to 
PDE4B. Such a model would be useful in medicinal chemistry to design other dual specificity 
PDE4/7 inhibitors that are structurally-related to BC54.  
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6.1.4 BC54 analogs have different chemical groups that are important for activity against 
PDE4B2  
As already mentioned, the knowledge about PDE structure helped understand amino acid 
interactions with each other in the catalytic site and their binding to inhibitors. In addition, many studies 
used PDE crystal structures to design PDE inhibitors. Therefore, I decided to examine the structure 
activity relationship (SAR) of BC54 using a series of related compounds. For this study, I profiled 
the potency of twelve compounds, which are structurally similar to BC54, in both a 5FOA-growth 
assay (where PDE inhibition stimulates growth) and an SC-ura halo assay (where PDE inhibition 
prevents growth), as shown in Appendix B. The purpose of these experiments was to identify 
chemical groups associated with changes in potency and selectivity.  
Five out of 12 BC54 derivatives showed some activity using strains expressing PDE7B and PDE4B, 
and the pattern of inhibition was consistent between the 5FOA growth assay and the SC-ura halo 
assay. BC54 itself shows some preference for PDE4B over PDE7B, consistent with a lower IC50 
for PDE4 (6.5nM; Chapter 3) than for PDE7 (140nM; Doug Ivey, unpublished data). Of the two 
most effective derivatives, BC54-8 shows a preference for PDE4B, while BC54-6 shows a 
preference for PDE7B, although neither is as effective as BC54 itself. The absence of a cyclohexyl 
group attached to the nitrogen of the pyrimidine ring in both analogs is one of the two main 
structural differences from BC54. In place of this group, BC54-8 has an isobutyl group and BC54-
6 has an isopropyl group. Since BC54-6 shows a preference for PDE7B over PDE4B, while BC54 
and BC54-8 show a preference for PDE4B over PDE7B, it can be inferred that these side-groups 
attached to the nitrogen of the pyrimidine ring are directly contacting the target enzymes. The 
second structural difference is in the acetylimino group attached to the carbon in the 2’ position of 
the pyrimidine ring. The double bond connecting this carbon to the nitrogen of the acetylimino 
group blocks the rotation of the acetylimino group. In both BC54-6 and -8 the acetylimino 
orientation is locked in one direction that distinct from the orientation in BC54. The same 
orientation of the acetylimino group of BC54 is seen in analogs -5, -7, -9 through -12. Although 
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these data are preliminary, these findings suggest that both the cyclohexyl side group and the 
orientation of the acetylimino group may be important for BC54 activity. Furthermore, three BC54 
analogs display moderate activity. These compounds are BC54-1, -3 and -11. BC54-1 and BC54-3 
also seem to have a stronger inhibition on a strain expressing PDE4B as compared to PDE7B, while 
BC54-11 seems to display the opposite preference. BC54-1 and BC54-3 lack the acetylimino group 
and replace this group with a double bond to NH (imino group). Also, BC54-3 has a methylcarboxyl 
group instead of the ethylcarboxyl group present in BC54 and BC54-1. In addition, BC54-11 has a 
methylfuran in place of the cyclohexyl group. The absence or substitution of the cyclohexyl group 
of BC54 may affect not only specificity, but cause a strong reduction in potency. These findings 
suggest that the cyclohexyl group is the most effective side-group in this position of those that have 
been tested, although it leaves open the possibility of identifying an even more effective group for 
this position. However, these data are preliminary and required enzyme assays to confirm our initial 
findings. 
Overall, all the compounds that had no effect against PDE4B- and PDE7B either 1) lack the 
cyclohexyl group, 2) lack the ethylcarboxyl group and/or 3) lack the acetylimino group. For 
example, BC54-5 is identical to BC54 with the exception of having only a methyl group in place 
of the cyclohexyl group. In addition, some compounds such as BC54-2 and BC54-7 possess 
additional atoms that may either abolish inhibition or prevent the compound from entering the cells. 
One could distinguish between these two possibilities by carrying out in vitro enzyme assays to 
determine IC50s for the various compounds. Overall, the BC54 derivative data along with the 
findings about PDE4BT407A mutant can help to validate docking models of BC54 bound to PDE4 
and PDE7 enzymes. This information can then guide efforts to design a new generation of more 
potent and soluble PDE inhibitors based on the BC54 structure. 
 
6.1.5 Conclusion 
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In the current study, both PDE4BY233H and PDE4BT407A mutant strains display an altered response 
to either BC54 or rolipram in cell-based assays. In the in vitro assays, the point mutation in the 
PDE4BT407A decreases its efficiency in hydrolyzing the substrate and decreases its affinity to the 
inhibitors. The decrease in the interaction with the substrate, can be seen in the decrease in Vmax, 
enzyme efficiency and turnover number. Based on the in vitro assay data, it seems that Thr407 is 
an important residue for both PDE4B enzymatic activity and for inhibition by BC54. Further, 
profiling of BC54 derivatives suggests that the acetylimino and cyclohexyl are important for 
potency and selectivity, respectively. The work performed with BC54 analogs was limited by what 
compounds currently exist in the collections of compound companies. Therefore, relatively few 
regions of the structure were varied. In the future, a project in collaboration with a chemist might 
allow us to look at portions of the compound that are the same in all these derivatives, but are 
identified as being important based on the T407A mutant. 
As the T407A substitution was only assessed in the context of the PDE4B2 enzyme, it will be 
interesting to introduce this change to the long forms of PDE4 to see if produces a more dramatic 
loss of sensitivity to rolipram than seen in our study. In addition, it will be important to introduce 
the T407A mutation into the PDE7 enzyme to investigate if a mutant PDE7 is resistant to BC54 as 
well, since the interaction between BC54 and PDE4 does not necessarily mimic that of the 
interaction between BC54 and PDE7. We have previously observed that a compound, BC8-15, that 
inhibits both PDE4 and PDE8 enzymes appears to interact with enzymes of these two families in 
significantly different orientations (Demirbas et al., 2013). Due to this difference, many related 
compounds completely lost activity against PDE8, while retaining activity against PDE4. 
Finally, these studies demonstrate that BC54 and rolipram act by contacting residues in the active 
site of these PDEs. Therefore, we are in a position to test our collection of PDE4 inhibitors against 
a strain expressing PDE4BT407A as a way of identifying compounds that act at a site other than the 
cAMP-binding site. These would likely be allosteric inhibitors, which could then be used to isolate 
compound-resistant PDE4 alleles in an effort to identify their site(s) or action.  
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In conclusion, we confirmed residues that affect PDE4B inhibitor binding and affinity for the dual 
specificity BC54 inhibitor. Furthermore, the results of BC54 derivatives help us understand that 
substituting side groups in the pyrimidine ring and/or in the ethylcarboxyl, and changing the 
orientation of the acetylimino group may enhance the inhibitors when designing the next generation 
of PDE4/7 inhibitors. Taken together, these findings help us to better understand the interaction 
between PDE4 and BC54, and will be useful to guide efforts to generate inhibitors with enhanced 
activity in medicinal chemistry. In the future, it might be possible to design drugs using the 
knowledge gained about BC54 to treat autoimmune conditions. 
 
6.2 The 10,000 HTS screen can identify compounds that reduce PKA activity 
I developed a HTS that was designed to identify compounds that reduce PKA activity by 
stimulating PDE activity. The stimulation of PDE activity is reflected by an increase of the GFP 
signal. 
 
6.2.1 Failure to validate compounds points out to technical issues 
While the screen identified a number of compounds that appeared to elevate the GFP signal, we 
were unable to confirm that any of the cherry-picked compounds were authentic PDE activators. 
There are different reasons that can explain the lack of compound validation. For example, it is 
possible that the active compounds are breakdown products of the compounds supposedly present 
in the wells of interest. For the primary screen, we use library plates that have been frozen and 
thawed a few times. These freeze-thaw cycles may degrade the compound to create new 
compounds. It is possible that it is the effect of the derivative and not the compound that led to the 
initial positive result in the primary screen. In the cherry pick assays, we use compounds prepared 
from the original stocks. These compounds may lack the breakdown products and therefore not 
retest as hits. In the counter screen assays, we purchase new compounds directly from the 
companies. When dissolving these compounds, we observe solubility issues or color changes that 
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can be an indication of fluorescence (Meanwell, 2011; Turek Etienne et al., 2003), which may 
suggest that they were false positives in the primary screen. These observations cannot be fully 
addressed using the compounds from the screening facility. 
A third reason why validation may have failed is that the cell delivery methods were completely 
different. In the primary screen, I used pin transfer. In the cherry pick assays, I used pocket tips that 
can fail to deliver the compounds properly, especially ones that fall out of solution in an aqueous 
medium. In the counter screens, we use multichannel pipettes for the assays. Multichannel pipettes 
can have problems delivering compounds due to not fully dispensing the compounds or formation 
of bubbles. It is worth noting that similar problems for validation were encountered in the screens 
for PDE inhibitors. 
For future screens, it will be important to use a method for cherry pick assays that gives us more 
information about the compounds’ potency and selectivity. A good alternative would be to perform 
a dose response against strains that express the initial target protein as well as nontarget proteins 
that carry out the same function. This way, we can separate selectivity versus potency before 
purchasing the compounds for in-house assay. Moreover, it is also important to expand the HTS. 
Finding PDE activators might be a rare event. Thus, a 10,000 HTS may not be sufficient to find a 
PDE activator. Furthermore, it will be good to perform future screens targeting different PDEs in 
parallel to decrease false-positives.  
 
6.2.2 Conclusion 
In conclusion, I have developed a HTS for small molecules that activate PDE activity. To our 
knowledge, this is the first HST developed with the effort to identify such compounds. For further 
optimization and validation of candidate hits, it will be important to expand the HTS using strains 
that express other PDEs. As an effort to identify PDE activators is to increase the number of 
compound libraries tested, which can help decreasing technical issues in the validation process. 
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Therefore, it might help find and characterize stronger hits versus weak hits using different strains 
expressing other PDE against a larger library screen.  
 
 6.3 Development of a HTS for PDE activators and AC/GNAS1 inhibitors 
While the 10,000 compound screen for PDE activators showed promise, it suffered from two issues. 
In the absence of a counter-screen strain, we could not differentiate between PDE activators and 
compounds that elevated the GFP/OD600 signal because they were either partially toxic or 
fluorescent. In addition, the relatively small number of compounds screened meant that it was 
possible there simply was not a PDE4 activator in this library. The HTS described in Chapter 5 
addressed both of these issues by using a counter-screen strain and expanding the compound 
libraries.  
The main goal of the larger HTS screen is to find compounds that reduce PKA activity by either 
activing PDE or inhibiting AC/GNAS1. We have recently developed the ability to express 
mammalian ACs along with the GNAS1 GS that stimulates the tmACs, which allowed us to 
construct strains that expressed multiple target proteins to enhance the ability to find novel chemical 
regulators of mammalian cAMP signaling. In addition, a combination of targeting AC inhibitors 
and PDE activators can help decreasing technical issues in the validation process. It is possible that 
AC inhibition promotes a greater increase in GFP signal in comparison to PDE activation. 
As already mentioned, I carried out this HTS with two strains simultaneously. The use of two 
strains aims to decrease the number of false positives due to fluorescence and toxicity as we would 
expect such compounds to show up as hits for both strains. The screening strain expresses PDE4D3 
and AC5 and the counter-screen strain expresses PDE7B1, AC1 and GNAS1. Both strains were 
chosen because they have similar basal levels of GFP signal. Thus, any changes in GFP signal for 
one but not for the other strain indicates a specific compound reducing PKA activity for that 
particular strain. In chapter 5, I described the HTS to screen 100,000 small molecules that might 
identify compounds that either activate PDEs or inhibit ACs/GNAS1.  
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After the primary screen, 727 compounds were confirmed as hits for the screening strain. The hits 
were calculated by measuring the median and MAD for the experimental samples (i.e., the 
compound-treated wells). I changed the method to calculate Z-scores during the screening process 
due to concerns raised by the ICCB facility staff when we noticed that we have many likely false-
positives due to the extremely low SDs of the negative controls. Such small SDs allowed for 
compounds to appear as a hit on only one strain due to slight differences in the MAD/median ratio. 
Once I changed the Z-scores analyses, I reached a reasonable and more realistic number of hits. 
For the cherry pick experiments, I selected 113 compounds that displayed either strong (above 15), 
moderate (10-15) or weak (6-10) Z-score values for both duplicates. 
To validate these compounds, I tested various doses of compounds in a GFP assay against four 
different strains, which included the screening strain. These strains expressed different 
combinations of PDEs with ACs and/or GNAS1. The goal was to verify specificity and potency. 
From the 113 cherry pick hits, 70 were reconfirmed as targeting the screening strain. However, 49 
compounds were eliminated on the basis of insufficient selectivity and potency and 17 were 
acquired for in house testing (along with 8 compounds obtained based on the primary screen alone). 
 
6.3.1 Methods to validate candidate hit compounds 
The 17 hit compounds that were reconfirmed in the cherry picks were purchased for further testing 
in secondary assays. In addition, we purchased six compounds (BC23-2, -3, -5, -6, -7,-8,-19) that 
were highly active hits in the primary screen along with a compound (BC23-1) that was designed 
based on structure similarity to both BC23-2 and BC23-3. A combination of cAMP and GFP assays 
were performed, but results were not reproducible. One possibility is that compounds failed to enter 
the cells using both methods. Another possibility is that the cAMP levels in the screening and 
counter-screen strains are already low that any further reduction in cAMP may not be readily 
detectable. Once more possibility is that we validated false positives that have either fluorescence 
or solubility issues that were not detected earlier. 
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Although, I encountered technical issues with the GFP assays, I was able to confirm that most of 
these compounds have no effect on non-target proteins by treating a yeast strain (CHP2053) 
expressing ExoY (Pseudomonas aeruginosa cyclase) with PDE5A and PDE9A (Figure 5.8).  
After cAMP and GFP assays, I performed a KCl assay. As mentioned in Chapter 1, strains with 
low PKA activity display KCl sensitive growth stress and strains with high PKA activity display a 
KCl resistant growth (Stiefel et al., 2004). The purpose of this experiment was to validate the 
compound hits independently from the fbp1-GFP reporter. In the KCl assays, I used strains that 
display KCl-growth resistance due to their relatively high level of PKA activity. These strains 
would become KCl-sensitive if a compound could reduce PKA activity. I confirmed that BC23-19 
is a toxic compound in the KCl assay (Figure 5.9). In addition, most of the candidate hits, as 
demonstrated with BC23-7 in Chapter 5, had no effect in the strains tested in KCl assay (Figure 
5.9). However, the data seemed less conclusive because it is possible that these compounds do not 
diffuse in solid medium and may still be able to either inhibit ACs or activate PDE4D3. Moreover, 
I confirmed that compounds BC23-18, -21 and -22 are AC5 inhibitors. However, these inhibitors 
are not AC5-specific inhibitors, as they display a broad AC specificity.  
 
6.3.2 Difficulty in detecting PDE activators may be related to the limitation in increasing the 
enzyme activity 
Although PDE activators have yet to be validated, it could be related to the fact that the increase in 
GFP signal due to an increase in PDE activity may have a low threshold effect. This, in turn, would 
lead us to prioritize PDE activators below AC inhibitors. An inhibitor can fully inhibit an enzyme 
activity, but an activator may be limited to no more than doubling the enzyme activity. The majority 
of compounds re-confirmed in the cherry pick assays were considered weak due to Z-scores values 
below 10 in duplicate wells. Therefore, it is possible that compounds that produce a slight increase 
in GFP signal may not be confirmed in the cherry pick experiments or counter-screen assays.  
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6.3.3 Progesterone is an AC inhibitor 
The use of two strains simultaneously allowed for detection of specific hits for each strain. The 
most potent candidate hit for the counter-screen was Progesterone (work to be continued in the 
Hoffman lab). Interestingly cathecol estrogens, structurally related to Progesterone, inhibited 
mammalian AC1, AC2, AC5 expressed in membrane preparations of insect cells and inhibited AC7 
in an in vitro assay (Steegborn et al., 2005). Moreover, this study confirmed that cathecol estrogens 
act as non-competitive AC inhibitors binding to a pocket near the active site (Steegborn et al., 
2005). Another study demonstrated that Progesterone inhibits adenylyl cyclase expressed in 
Xenopus oocytes (Sadler et al., 1984). Although there is evidence that Progesterone is an AC 
inhibitor, its specificity is unknown. In our study, Progesterone was initially identified as a hit for 
the counter-screen that expresses AC1. Following counter-screen experiments in our lab, it seems 
that Progesterone may be a broad specificity AC inhibitor. Therefore, I can conclude the use of our 
yeast HTS system can not only detect AC inhibitors, but can identify AC inhibitors with broad 
specificity. However, this characterization is not complete. 
 
6.3.4 Using non-selective compounds to understand the mechanism of AC regulation 
I have confirmed BC23-18, -21 and -22 are AC inhibitors using KCl assays. All these compounds 
seem to target AC5, one of the proteins of interest expressed in the screening strain. However, they 
also target other ACs. However, further testing needs to be performed for further characterization 
of potency and specificity.  
Most of the current AC inhibitors were designed based on tmAC structure, mainly targeting the 
catalytic site (Seifert et al., 2011; Pavan et al, 2009). However, it is difficult to develop AC 
inhibitors due to the fact that the target protein is an integral membrane protein that creates 
challenges for in vitro enzyme assays, which generally rely on purified targets. Furthermore, many, 
but not all, inhibitors have low potency inside the cells with the use of concentrations greater than 
100µM to elicit any effect, but with that comes the possibility of off-target effects (Seifert et al., 
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2011). Our screen assessed AC inhibitors inside the cells in a much lower concentration depending 
on the method of compound delivery (below 25 µM for Primary screen and 5 µM and lower 
concentrations for cherry picks). In addition, several studies failed to assess their action inside the 
cell due to their hydrophilic nature. To our knowledge, this is the first time a research group has 
identified AC5 inhibitors using a yeast system for a large HTS, instead of design of compounds, 
and assessment of the inhibitor activity inside the cell. The only other AC inhibitor screen I am 
aware of was a small compound screen by Conley and colleagues (2013) for AC2 inhibitors using 
mammalian cell culture.  
The validated AC5 inhibitors display a broad inhibition targeting different ACs. BC23-18 and 
BC23-21 inhibit AC1 and AC8 (group I), AC2 and AC4 (group II), AC5 and AC6 (group III), and 
AC9 (group IV). However, BC23-21 appears to inhibit AC5 and AC6 more strongly than BC23-
18 as judged by an increased zone of inhibition on KCl plates. BC23-22 inhibits more strongly 
AC7, AC8 and AC9, while inhibiting weakly AC4, AC5 and AC6. Although the preliminary data 
are encouraging, IC50 assays will be required to quantitate potency and selectivity. In the future, 
this broad specificity may be useful as certain ACs have similar tissue distribution even if they do 
not belong to the same group (Seifert et al, 2009). In addition, subsequent screens of this collection 
using strains that express other mammalian ACs or cyclases from other organisms should allow us 
to identify compounds that were overlooked in this screen as being ones worthy of further 
examination. 
When I started the HTS, we looked for compounds that selectively affected only one of the two 
strains that were screened. We may have set our sights too high in expecting highly selective hits. 
It is possible we overlooked some of the best AC inhibitors by requiring them to distinguish 
between AC1 and AC5. Non-selective AC inhibitors can be used to make a collection of related 
compounds and screening them for increased potency and selectivity. This was the approach 
initially used by the PDE scientific community using theophylline, a non-selective inhibitor, to 
design family-specific compounds that could be used in cell-based assays to investigate the roles 
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of specific ACs just as PDE inhibitors are used to study individual PDE isoforms (Houslay et al., 
2005).  
The discovery of non-selective AC inhibitors allows me to question our analyses for the Primary 
screen. At this stage, I believe that finding AC inhibitors is the best approach to understand the 
biological consequence of AC inhibition inside the cells. Further, due to detection of broad 
specificity AC inhibitors one can infer the need to reassess the primary screen candidate hits list 
since we might have eliminated stronger AC inhibitors that were also hits for the counter-screen. 
Perhaps, I may have eliminated compounds that have either more potency and/ or display 
specificity for fewer ACs. 
 
6.3.5 Conclusion and Future directions 
In summary, I developed a HTS for PDE activators and AC/GNAS1 inhibitors. Overall, I was able 
to identify compounds that appeared to be specific to the screening strain based on the increase in 
GFP levels, a function of reduction in PKA activity. I confirmed and validated three AC5 inhibitors 
using cell-based assays. These inhibitors have somewhat a broad AC inhibition, but they can 
specifically inhibit members from groups I, II, III, and IV of tmACs. This is a very promising 
finding for the development of specific AC inhibitors, but further characterization is required. If I 
were to continue working on this project, I would probably perform counter-screens in some of the 
compounds hits that were eliminated in the primary screen. Clearly, the future direction of this 
project is to expand the HTS using strains express other tmACs and other PDE4 isoforms. By 
having more data on the effects of these compounds using a collection of strains, we can identify 
AC inhibitors that act on more than one AC as well as PDE activators that may have only a 
moderate impact on the GFP signal. This approach will increase our knowledge about potency and 
specificity of these small molecules and help us optimize the conditions to validate the candidate 
hits. This HTS will also serve as a database for future HTS conducted in our lab for small molecules 
that reduce PKA activity. 
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APPENDIX A 
DEVELOPMENT OF S.POMBE GENETIC SCREEN FOR -
COMPOUND- RESISTANT PDE7 ALLELES  
INTRODUCTION 
As mentioned in Chapter 1, our lab has developed a cell-based platform to screen for PDE7 
inhibitors using genetically engineered yeast strains. Currently, we have small molecules that 
inhibit many PDE proteins specifically. Here, we developed a genetic screen in an effort to 
characterize the interaction between PDE7 inhibitors, and the PDE7B enzyme by screening for 
compound-resistant mutant PDE7B alleles. Our approach takes advantage of the mating phenotype 
that is associated with low PKA activity as mentioned in Chapter 1. Mutant alleles of cAMP-
specific PDE7 gene can be detected by their ability to increase mating in the presence of a specific 
PDE7 inhibitor. Thus, we have developed genetic screens for mutant alleles of mammalian PDE 
genes that are altered for their sensitivity to chemical inhibitors.  
 
MATERIALS AND METHODS 
A1. MATERIALS 
A1.1 Growth media 
Sensitivity to compound PDE inhibitors was determined in (5FOA) and SC-solid medium as 
described by Hoffman and Winston (1990). 
 
A1.2 Yeast strains 
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The genotype of all yeast strains used in this study are listed in Table A1. The strains in this thesis 
carried either the fbp1-ura4+. Both constructs are translational fusions integrated at the fbp1+ locus, 
as previously described by Hoffman and Winston (1990) and de Medeiros et al. (2013), 
respectively. Strains were grown at 30ºC. 
 
A.1.3 Enzymes 
Restriction endonuclease enzymes and their buffers were purchased from New England Biolabs 
(NEB, Ipswich, MA) and used according to NEB instructions.  The enzymes used in this study 
were HindIII. PvuII and XhoI for D7 
 
A2. Methods 
A.2.1 Mutagenic PCR 
Mutagenesis PCR was performed to clone either the mammalian PDE7B1 (Genbank accession 
number NM_018945) as described in section 2.2.2. PCR products were generated by FailSafe 
PCR kit already using “Premix" buffers A, B, E, F, K and L as described in section 2.2.2. The 
primers used were the cgs2mut5’ and cgs2mut3’ described in section 2.2.2. Mutant plasmid 
candidates were rescued out of yeast into E. coli by using the Smash and Grab method (Hoffman 
and Winston, 1987), and purified using a QIAquick PCR Purification kit, according to 
manufacturer’s instructions (QIAgen®, Valencia, CA) and sent out for sequencing. 
 
A.2.2 Cloning and Plasmid construct 
Mutant plasmid candidates were constructed as described in section 2.1. After sequencing, plasmids 
containing mutant candidate PDE7B1 alleles for the mating phenotype were integrated into the 
chromosome of a S. pombe strain (CHP1207) carrying the cgs2-2 frameshift allele (no PDE 
activity) along with an adenylyl cyclase deletion (git2∆), carrying either the fbp1-ura4, as 
previously described (section 2.1.1).  
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Table A1. Strain list used in the genetic screen for mating 
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A.2.3 DNA sequencing 
The purified plasmids were sent out to Eurofins MWG Operon (Huntsville, Alabama) for DNA 
sequencing and confirmation of base-pair change. The following primers were used: cgsmut5’ 
(5’TCATAGCATACTTCTTCACCAAGC3’) and cgsmut3’ 
(3’AAAGTGTCCGATGAGAAAAGCGTG). 
 
A.2.4 Genetic Screen 
A genetic screen was developed in the present study to identify and isolate compound-resistant 
PDE7B1 alleles by their ability to increase mating even in the presence of a PDE7 inhibitor (Figure 
A1). In the first phase of the screening, three strains were chosen where PDE activity can be 
detected by evaluating the cAMP levels required to confer growth response. The first step for the 
screen was to perform mutagenesis PCR to generate mutant candidates. Then, the S. pombe cgs2 
gene was replaced with human PDE7B1 gene, inserted it into a plasmid, and cotransformed them 
into three chosen strains (Table A1). The strain CHP1440 (no cAMP activity) had few 
transformants and strain CHP1251 (reduced cAMP levels) did not allow us to differentiate 
transformants from empty vector control, while strain SP578 (normal cAMP levels) produced a 
number of transformants amenable to this study. Therefore, strain SP578 was chosen for the 
continuation of the screen. After that, the mating phenotype was detected by utilizing iodine vapor 
(Egel, 1989). I screened for alleles that allow mating in the presence of the compound. The iodine 
staining was performed initially onto a plate. Initial stained cells were transferred to liquid medium 
for a second mating characterization where 220 colonies were identified. However, accuracy of 
mating can be masked in both staining procedures. In order to make a better assessment, each of 
the 220 colonies was verified under microscope. These colonies were then transferred to new 
medium in presence/absence of compounds and stained again. From 220 colonies screened, 10 
candidate colonies were selected and plated to assess mating phenotype in solid medium in the 
presence/absence of compounds. Finally, 5 candidate colonies with mutant PDE7B alleles that were 
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obtained demonstrated altered patterns of iodine staining, where mating was either increased (G21, 
L1) or decreased (D7, F22) and no change was observed in colonies carrying the wild type PDE7B 
allele (K19) in the presence of the PDE7B inhibitor (BC12). These plasmids were rescued out of 
yeast into E.coli to be purified and sequenced.   
 
A.2.5 Cell-based assays 
Plasmids were integrated into CHP1207, as described in the previous section. Characterization of 
mutant PDE7B1 candidate alleles in the presence of exogenous cAMP and confirmation of altered 
behavior in the presence of PDE7B inhibitors (BC12, BC28, BC30 and BRL50481) were 
performed with 5FOA assays, as previously described (section 2.1.3.1). 
 
A2.6 Two- step PC to generate single missense mutations 
In order to determine which mutation in each PDE7B mutant alleles was responsible for the initial 
altered behavior detected in the screen, the two-step PCR was used. This technique aimed to 
reproduce the point mutations near or close to the catalytic domain in the wild type human PDE7B1 
gene (Genbank accession number NM_002603). The technique was performed as previously 
described (Mudge et al., 2012). The two sets of primers used for mutant C7 were: C7For 5’- 
CTCTTTGTAATCAATCCCTAGTATAC-3’ and cgs2mut3’; C7Rev5’-
GTATACTAGGGATTGTTACAAAGAG-3’ and cgs2mut5’. The two sets of primers used for 
mutant D7 were: D7For 5’-GGGTCTGTGAAGAAGGCAAGGTGAAC-3’ and cgs2mut3’; 
D7Rev5’GTTCACCTTGCCTTCTTCACAGACCC-3 and cgs2mut5’. The primers cgs2mut5’ and 
cgs2mut3’ were described in section 2.2.2. 
After that, PCR products were sent out for sequencing to confirm that each point mutations was 
introduced. The following sets of primers were used for both mutants: PDE7627F 
(TGCAGCAGCACACGATGTGG), PDE7B1199R (5’ TCCGACAGGGTGCTGTTACC3’), 
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cgsmut5’ and cgsmut3’. After that, 5FOA assays were performed to reconfirm the altered mating 
phenotype. 
 
 RESULTS 
The candidate mutant plasmids were integrated into a strain carrying an adenylyl cyclase deletion 
(git2Δ) to better understand its behavior. A mutant strain (CHP1505) that has WT sequence was 
used as a control to determine the best growth conditions in which the mutant strains should be 
further tested in a 5FOA assay. The amount of exogenous cAMP needed to activate PKA and 
promote 5FOA growth is a reflection of PDE activity. It also identifies conditions where compound 
sensitivity can be examined. When the growth curve moves towards the right, the enzyme is more 
active, whereas when the growth curve moves towards the left, the enzyme is less active (Figure 
A2). In this experiment, two mutant PDE7B strains (CHP1503 and CHP1506) had lower enzyme 
activity when compared to the wild type PDE7B strain (CHP1505), while mutant PDE7B strain 
CHP1502 had similar PDE activity to the wild type PDE7B strain (CHP1505). In addition, two 
mutant PDE7B strains (CHP1501 and CHP1504) had a higher PDE activity in comparison to the 
wild type PDE7B strain. Also, the addition of 0.2 mM cAMP was found to be an optimal condition 
for the secondary screening assay (5FOA growth assay), promoting growth while PDE activity 
remained low (Figure A2).  
After characterizing the optimal growth conditions in the cAMP dose response assay, a secondary 
screening assay was performed. Six candidate mutant strains (Table A1) were tested for sensitivity 
with PDE7B inhibitors (BC15, BC28, BC30 and BRL50481) in the 5FOA growth assay. The 
CHP1505 strain expressing wild-type PDE7B was used as the control. In comparison to the wild- 
type PDE7B strain, two PDE7B strains (CHP1502 and CHP1503) had altered response to 
compound BC12 and one PDE7B strain (1503) had no response to compound BC28. In addition, 
one PDE7B strain (CHP1503) was hypersensitive in the presence of compound BC30 and all 
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Figure A1. Development of a genetics screen. A)  Gap repair was performed to clone mutagenic 
PDE7B PCR products into the plasmid. B) Genetic screen protocol. C) Screen using in mating 
analysis in presence (+) or absence (-) of compound BC12. 
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Figure A1 
 
 
  
209 
 
PDE7B strains had similar response to compound BRL50481, the commercially-available specific 
PDE7 inhibitor (Figure A3). Taking all data into account, I concluded that two mutant PDE proteins 
(strains CHP1502 and CHP1503) appeared to have an altered sensitivity to our compounds, but not 
to the commercially available PDE7 inhibitor (BRL50481). Further studies will be performed with 
these mutant PDE proteins. 
Based on sequencing data, the two mutant candidate PDE7B plasmids, identified as C7 (inserted 
into strain CHP1502) and D7 (inserted into strain CHP1503) carry three and two candidate 
mutations, respectively (Figure A4). Therefore, I performed site-directed mutagenesis to isolate 
and investigate mutations that both mutant plasmids carry within/near the catalytic domain of 
PDE7B allele. The amino acid substitution of the D7 plasmid is from Phenylalanine to Leucine. 
While the C7 plasmid carries an amino acid substitution from Aspartic Acid to Glycine. After 
isolation of the mutations of interest, 5FOA assays were performed. However, the initial altered 
behavior from the screen was not confirmed (data not shown). 
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Figure A2. cAMP curve. 5FOA growth assays of strains expressing wild type PDE7B (CHP1505) 
and five candidate mutant PDE7B proteins (CHP1501, CHP1502, CHP1503, CHP1504 and 
CHP1506) in the presence of four PDE7 inhibitors (BC12, BC28, BC30, BRL50481). Values 
represent the average of OD600 ± standard error from one independent experiment. The values 
within each experiment represent an average of four replicate wells. Each experiment was 
incubated for a 48h growth at 30ₒC. 
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Figure A2 cAMP curve 
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Figure A3. Growth response of candidate mutant PDE7B alleles to different compounds in 5FOA 
medium. PDE7B strains growth response in the presence of compounds: A) BC12, B) BC28, C) 
BC30 and D) BRL50481. Optical density of cultures of mutant PDE7B strains grown in 384 well 
microtiter wells. Values represent the average of OD600 ± standard error from two independent 
experiments. The values within each experiment represent an average of four replicate wells. Each 
experiment was incubated for a 48h growth at 30ₒC. Region of high sensitivity is highlighted by 
black rectangle and emphasized on top right (C). 
  
213 
 
 
Figure A3 Growth response of candidate mutant PDE7B alleles to different compounds in 
5FOA medium 
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Figure A4. Sequence homology of PDE7A and PDE7B the catalytic domains. A) PDE7B catalytic 
domain is depicted in blue. PDE7A catalytic domain is depicted in grey. Location of plasmid D7 
mutations (Strain CHP1503) are in yellow. Location of plasmid C7 mutations (Strain CHP1502) 
are in red. B) Co-crystal structure of PDE7A. C) Co-crystal structure of PDE7A depicting 
localization of the two residues of mutant PDE7B alleles (F345L in CHP1503; D368G in 
CHP1502). 
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Figure A4 Sequence homology of PDE7A and PDE7B the catalytic domains 
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CONCLUSIONS 
Yeast genetics can be used to study mammalian genes. In this study, compound sensitivity, mating, 
growth phenotype and cell viability can be associated with PKA activity. In this study, I have 
successfully developed a genetics screens to study human PDEs analyzing the mating phenotype 
in the presence of PDE7B inhibitors. These mutants PDEs were isolated and further characterized. 
However, the initial phenotype was not confirmed suggesting the altered behavior was a result of 
a combination of mutations and not to a specific amino acid change. In future experiments, it will 
be important to optimize conditions that will generate mutants carrying point mutations for 
confirmation of the phenotype and, consequently, understanding the PDE and its specific inhibitors 
mechanism of interaction. In conclusion, we have successfully developed a genetic screen looking 
for altered mating phenotype. In the future, it will be interesting to develop other screens analyzing 
other phenotypes associated with PKA activity. 
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APPENDIX B 
CHARACTERIZATION OF BC54 ANALOGS IN LIQUID 
AND SOLID MEDIA 
INTRODUCTION 
 
As described in Chapter 2, compound BC54 is a potent and selective inhibitor of PDE4 and PDE7 
enzymes. Here, we examined a collection of compounds related to BC54 in an effort to identify 
important functional groups in the compound. This was done using two assays. In the first, 
compounds were assessed for their ability to inhibit growth on SC-ura medium of strains expressing 
either PDE4B or PDE7B (Ura+ growth due to fbp1-ura4 expression is associated with low PKA 
activity). In the second assay, compounds were assessed for their ability to stimulate 5FOAR growth 
due to activation of PKA to repress fbp1-ura4 expression. 
 
MATERIALS AND METHODS 
 
B1. MATERIALS 
B1.1 Growth media 
Sensitivity to compound PDE inhibitors was determined in (5FOA) and SC-solid medium as 
described by Hoffman and Winston (1990). 
B1.2 Yeast strains 
The genotype of yeast strains, CHP1209 and CHP1268, used in this study are listed in Table 2.1 
(section 2.1.2). These strains carried the the fbp1-ura4+.construct, a translational fusions integrated 
221 
 
at the fbp1+ locus, as previously described by Hoffman and Winston (1990). Strains were grown at 
30ºC. 
 
B2. Methods 
B.2.1 Cell-based assay 
5FOA assays were performed in the presence of BC54 and its analogs, as previously described 
(2.1.3.1). 
 
B2.2 Growth in SC-ura 
The SC-ura growth phenotype is associated with PKA activity, as previously mentioned (section 
1.19) and depicted in Figure 6. 
 
RESULTS 
The activity of twelve BC54 analogs have been tested in solid media by growth in SC-ura medium 
and 5FOA assays. The results observed will be described in the sections below. 
 
B1. Profiling the potency of BC54 analogs 
The growth phenotype of yeast strains in SC-ura is associated with reduced PKA activity. Strains 
expressing either PDE4B (CHP1268) or PDE7B (CHP1209) in SC-Ura medium. Growth occurs in 
the presence of DMSO due to PDE activity. The PDE inhibition prevents growth by activating PKA 
in the presence of dual PDE7B/4B inhibitor, as depicted in the further left in Figure B1. Five out 
of twelve BC54 analogs (BC54-1/3/6/8/11) had moderate action against either PDE4B or PDE7B 
(Figure B1). The analogs BC54-1/-3/-8 seemed to inhibit more strongly strains expressing PDE4B 
plasmid (Figure B1, lower panel). While analogs BC54-6/-11 seemed to selectively inhibit strains 
expressing PDE7B plasmid (Figure B1, top panel). BC54 derivatives (BC54-4/5/7/9/10/12) had not 
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effect against either PDE4B or PDE7B (data not shown). The lack of activity of seven of the BC54 
analogs may be due to a failure to be taken up by the cell. 
 
B2. Profiling of BC54 analogs in cell-based assays with an effect 
5FOA Growth assays with strains expressing either PDE7B or PDE4B in the presence of BC54 
derivatives were performed. As already mentioned in previous sections, BC54 is a very potent 
inhibitor with dual specificity targeting PDE4 and PDE7 previously screened by our lab. In these 
assay, BC54 is the most potent inhibitor with dual specificity in both PDE7B and PDE4B strains 
(Figure B2a, b). While, BC54-6 and BC54-8 had a moderate inhibition against both strains in 
comparison to BC54 treatment, but more specifically against PDE7B (Figure B2a) and PDE4B 
(Figure B2b), respectively. BC54-1 had a weaker inhibition only against PDE4B (Figure B2b). The 
other BC54 derivatives (BC54-3 and BC54-11) initially screened in solid medium (Figure B1) did 
not inhibit in the secondary screen (Figure B2a, b), which it could suggest that the initial screen 
was a toxicity effect instead of inhibition. 
 
B3. Analyzing the structure of BC54 analogs  
The most potent derivatives, BC54-6 and BC54-8, don’t have cyclohexyl side group attached to 
nitrogen in the pyrimidine ring (Figure B3, top panel). Instead of the cyclohexyl side group isobutyl 
group and BC54-6 has an isopropyl group near the pyrimidine ring. In addition, BC54-11 has a 
moderate effect, contains a methyl furan instead of the cyclohexyl present in BC54 (Figure B3, left 
lower panel). While BC54-1 and BC54-3 compounds differ structurally from BC54 for the absence 
of the acetylimino group (Figure B3, mid and lower panel). From these two, BC54-1 has a methyl 
carboxyl group and BC53-3 has the ethyl carboxyl groups that is present in BC54.  
Seven compounds did not have any effect either in solid or liquid media (Figure B4). Compounds 
BC54-2 and -4 have the cyclohexyl group, but lack the acetylimino and ethyl carboxyl groups. The 
acetylimino group is also altered in compound BC54-7. Compounds BC54-5, -7 and -9 through -
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12 (has a similar structure to BC54-11) lack the cyclohexyl group, which was substituted by other 
side groups. 
 
CONCLUSIONS 
Yeast genetics can be used to study mammalian genes. We have previously screened for mutant 
PDEs resistant to BC54. Screening for BC54 derivatives is a good way to understand BC54 
structure and, consequently, potency. Based on our data, it seems that the cyclohexyl and 
acetylimino groups present in BC54 are important for its dual specificity targeting PDE4 and PDE7. 
In future experiments, it will be good test other BC54 analogs and perform in vitro assays to 
determine their IC50 concentrations. In conclusion, chemical screens can help elucidate the 
mechanism of interaction of PDEs and their specific inhibitors. 
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Figure B1. Growth phenotype in SC-Ura medium. Strains expressing either PDE4B (lower panel) 
or PDE7B (top panel) treated with BC54 analogs. Plates were incubated for 3 days at 30ₒC. 
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Figure B1 Growth phenotype in SC-Ura medium 
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Figure B2. 5FOA Growth assays in the presence of BC54 derivatives. A) Strain expressing either 
PDE7B or B) Strain expressing PDE4B were treated with five BC54 analogs along with BC54. 
Values represent the average of OD600 ± standard error from three independent experiments. The 
values within each experiment represent an average of four replicate wells. Each experiment was 
incubated for a 48h growth at 30ₒC. 
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Figure B2 5FOA Growth assays in the presence of BC54 derivatives 
A 
 
B 
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Figure B3. Chemical structure of BC54 analogs with an effect 
From top left to right indicate the structures of the following: BC54, BC54-4 and BC54-8. 
Structural differences are highlighted with red arrow. From bottom left to right indicate the 
structures of the following: BC54-11, BC54-1, BC54-3. 
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Figure B3 Chemical structure of BC54 analogs with an effect 
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Figure B4. Chemical structure of BC54 analogs with no effect 
From top left to right indicate the structures of the following: BC54, BC54-4 and BC54-8. 
Structural differences are highlighted with red arrow. From bottom left to right indicate the 
structures of the following: BC54-11, BC54-1, BC54-3. 
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Figure B4 Chemical structure of BC54 analogs with no effect 
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